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Chapter 1
General introduction
Genera] introduction
In industrialized countries hypertension is a major risk factor for cardiovascular
complications. Although the prevalence of this disorder in The Netherlands is not
exactly known, it is estimated to be approximately 15 to 20 %'. We are dealing,
therefore, with a serious health problem. Over the last twenty years many large-
scale therapeutic trials have been performed which have clearly shown that
antihypertensive treatment confers substantial benefit. The number of strokes may
be reduced by as much as 40%, and although the effect of treatment on cardiac
sequelae is less pronounced, one may still expect a 20% reduction in coronary
events*. In absolute terms the greatest benefit of treatment may be expected in
elderly patients and in those with more severe or complicated hypertension'.
In the second half of this century many antihypertensive drugs have been develo-
ped but, so far, none has proved to be the ideal agent. With any antihypertensive
drug the response rate, that is the number of patients in whom blood pressure
adequately falls, is somewhat in the order of 30 to 60%*. All agents which are
available today have been fairly well characterized in terms of their pharmacologi-
cal properties, but the mechanisms whereby they lower pressure in the intact
individual are only poorly understood, if at all. Surely, diuretics lower extracellular
volume (at least initially), most beta-adrenoceptor blocking drugs lower cardiac
output and renin and angiotensin converting enzyme inhibitors reduce the formation
of angiotensin II. Those features, however, still provide insufficient explanation as
to why they lower blood pressure. When one meticulously studies the effects of
antihypertensive agents on various aspects of blood pressure control, it soon
becomes clear that many of these agents act through multiple pathways. But even
then it remains difficult to explain why blood pressure falls, not the least because
short-term and long-term effects may differ considerably. Part of this problem may
be related to uncertainty about the actions of a particular drug, but a large part may
also be due to our incomplete understanding of the regulation of blood pressure.
Precisely the latter was the impetus for the studies described in this thesis.
Hemodynatnically speaking, blood pressure is determined by cardiac output and
total peripheral vascular resistance. From a theoretical point of view, therefore,
both cardiac and vascular factors could be involved in the pathogenesis of essential
hypertension. However, it is now generally accepted that the prime abnormality in
essential hypertension is a rise in vascular resistance'. In its early phase the
vasoconstriction of hypertension is to a large extent related to functional abnormali-
ties but with time structural alterations in the vessel wall (media hypertrophy)
contribute progressively to the rise in resistance*.
Which are the abnormalities that promote vasoconstriction in hypertension-prone
individuals' In this respect enhanced sympathetic activity and/or activation of the
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renin-angiotensin system are likely candidates. Although multiple lines of evidence
support the notion that these systems play at least some role in the pathophysiology
of essential hypertension, definite proof for their primacy is still lacking. Numerous
other systems have also been studied but so far the origin of high hkxxi pressure
has not been elucidated. Whatever the primary cause of hypertension may be,
according to Guy ton the kidney must be involved as welf. In his theory any rise in
pressure will eventually be offset by increased natriuresis. Only when the kidney is
not able to augment sodium output, blood pressure will rise by virtue of a relative-
ly expanded volume. It is not surprising, therefore, that many investigators have
directed their research efforts towards the kidney. The work described in this thesis
also bears testimony of such an approach.
When it comes to the study of the kidney in hypertension, a few aspects need
particular attention. These are renal hemodynamics, sodium homeostasis and
regulation of the renin-angiotensin system. All three factors are involved in blood
pressure control and derangements in any of these systems could, either alone or in
concert, contribute to the development or maintenance of high blood pressure.
Interestingly, both renal hemodynamics and renin are affected by (changes in)
sodium intake. It has also long been known that a high sodium intake may lead to a
rise in blood pressure. It is totally unclear, however, through which pathways this
occurs. First of all, not everybody responds to a higher sodium consumption with
an increase in pressure. This observation has led to the concept that there are
sodium-sensitive and sodium-resistant individuals". Secondly, hemodynamic and
neurohumoral responses to alterations in sodium intake may vary widely from one
individual to the other*"". One has to bear in mind, however, that the kidney is the
ultimate organ regulating sodium balance. If, for instance, sodium intake is
suddenly lowered, the kidney needs to reduce sodium output in order to maintain
sodium balance and to achieve a new steady state where output matches intake.
Several renal and extrarenal mechanisms contribute to this adaptation of the kidney.
However, if for some reason the renal response is inadequate (too slow, too last,
or otherwise inappropriate) one could imagine that extracellular volume suddenly
changes to such an extent that it affects blood pressure.
Although there are many studies in the literature which suggest that, notably in
sodium-sensitive subjects, changes in sodium intake are associated with alterations
in weight there is very limited information on the actual changes in cumulative
sodium balance. This is surprising, because one really cannot interpret modulations
in renal hemodynamics or renin activation without some appreciation of the amount
of sodium that is lost or gained by the body during manipulation of dietary salt
intake. This prompted us to set up a series of studies aimed at characterizing the
respective roles of sodium balance and renin in determining the final changes in
blood pressure in hypertensive patients who were faced with a sudden drop in
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sodium intake. Since the initial studies pointed to renin as the major determinant of
the changes in blood pressure we then proceeded with a number of additional
experiments to better define the pathophysiological actions of the renin-angiotensin
system. In particular, we were interested in the role of angiotensin II in the
regulation of renal hemodynamics and renin release. Moreover, we wanted to
explore whether tissues respond differently to circulating and to tissue angiotensins.
The following questions are addressed in this thesis: .
1) How does the hypertensive kidney respond to a sudden reduction in sodium
intake? What are the time course and the pattern by which sodium excretion is
matched to the new intake (Chapter 2)?
2) Can inter-individual variations in blood pressure changes during a sudden
reduction in sodium intake be explained by differences in cumulative sodium
loss (Chapter 3)?
3) To what extent do changes in cumulative sodium loss and activation of the
renin system interact during a sudden reduction in sodium intake? Does the
degree of renin activation predict final changes in blood pressure (Chapter 4)?
4) Given the importance of the renin-angiotensin system in both sodium homeos-
tasis and blood pressure control, what are the effects of circulating angiotensin
I and II on the kidney? Can the effects of angiotensin I on the kidney be
explained by intravascular conversion of this peptide or to angiotensin II that is
formed intrarenally (Chapter 5)?
5) Is it possible to discriminate in man between the effects of circulating angio-
tensin II and those of tissue angiotensin II (Chapter 6) ?
6) What is the effect of sodium intake on the responses to circulating and tissue
angiotensin II (Chapter 7)?
The data that have been generated by the various studies are discussed in more
detail and in the light of information from current literature in Chapter 8.
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Chapter 2
Heterogeneous patterns of
sodium excretion during sodium
restriction in essential
hypertensive patients
MME Krekels, AJHM Houben, ATJ Lavrijssen,
PN van Es, PW De Leeuw
J Hum Hypertens 1996; 10 (suppl 3): S123-S126
Abstract
Objective
The present study was performed to assess the sodium excretory pattern by which
sodium balance is reached.
Methods
Ninety untreated essential hypertensives with a median age of 47 (range: 18-70 yrs)
were admitted to a metabolic ward for seven days and put on a sodium diet of
55 mmol/day. During these seven days urinary excretions of sodium, potassium
and creatinine were determined daily along with mean arterial pressure (MAP) and
weight.
Results
Changes in urinary sodium excretion were not uniform, but according to the
pattern of attaining sodium balance, subjects could be divided into four groups.
Group 1 (n = 31) gradually reached sodium balance, whereas group 2 (n=10)
showed an abrupt fall in sodium excretion on the third day and an extremely
fluctuating sodium excretion thereafter. Group 3 (n = 32) reached sodium balance
on day four, but displayed a rise in sodium excretion during the following days and
group 4 (n= 17) attained sodium balance only very slowly or not at all. Compared
to the other groups, group 4 lost more sodium and at the same time displayed a
greater fall in blood pressure.
Conclusion
Our data suggest that there may be at least four different patterns by which sodium
balance can be reached following a reduction in sodium intake. The determinants of
these responses remain, however, elusive.
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The kidney quickly responds to alterations in dietary sodium intake by increasing
or decreasing renal sodium excretion. Several studies, both in man and in animals,
have reported that changes in renal sodium output during salt restriction are
compatible with a first order exponential process' \ In some of these studies,
however, subjects were not admitted to hospital, but rather followed up on a out-
patient basis. Thus, the data obtained under such circumstances may have been
subject to error. In some other studies we are not informed about the localization
of the study. In our own laboratory sodium balances which were determined in
hypertensive subjects during sodium restriction for the sake of other experimental
protocols, showed great variability and certainly not in all patients changes in
sodium excretion mimicked a first order exponential process. The present study,
therefore, was undertaken to study the renal adaptation to a sudden change in
dietary sodium intake in more detail.
Subjects and methods
Subjects
Only patients with uncomplicated essential hypertension and normal renal function
(serum creatinine less than 120 ^mol/1) were included in the present study. In
addition, to be eligible, 24 hour urinary sodium excretion had to be at least 70
mmol on multiple occasions prior to admission. Antihypertensive treatment, if any,
was stopped at least three weeks prior to the study (six weeks in case of diuretics).
The study was approved by the Ethics Committee of the hospital and written
informed consent was obtained from all patients after an explanation of the
protocol.
Protocol
Patients were admitted to a metabolic ward for the duration of 8 days. They
received a sodium-restricted diet which contained 55 mmol of sodium and 70 mmol
potassium per day. Caloric intake remained constant during the study period and
was calculated on an individual basis. Patients were allowed to walk around, but
they had to be in the supine position for at least 20 minutes prior to blood pressure
measurements. Twenty-four hour urine collections for determination of sodium,
potassium and creatinine were started immediately after admission and continued
for the remainder of the hospital period.
Mean arterial pressure (MAP) was measured every hour by Dinamap (Tampa,
17
Florida) and averaged for each day. In addition, weight was determined daily. ;
Statistical methods - :.' . - . , ; . •»
Differences between groups were analyzed by the nonparametric Kruskall-Wallis
test. As data were not normally distributed, they are expressed as medians and
ranges.
Results u
Ninety patients with uncomplicated essential hypertension and a median age of 47
yrs (range 18-70) were enrolled in this study. Initial urinary sodium excretion was
140 (70-328) mmol/24 hour for the whole group. Urinary creatinine excretion
during the entire study period averaged 13.5 mmol/24 hours (range 5-28.5) When
changes in sodium excretion following initiation of sodium restriction were
analyzed for all patients together, the observed pattern was consistent with a first
order exponential process (figure 1). On average, however, sodium excretion
varied greatly between subjects, even after seven days (figure 1). Obviously, at a
time where patients were supposed to be in sodium balance and sodium output
should be around 50-60 mmol/day in all patients, the variability in sodium
excretion was as great as prior to sodium restriction. In fact, 24 hour sodium
excretion ranged from 69 to 273 (median:96) mmol on day 2 and from 1 to 115
(median:57) mmol on the last day.
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figure I. Time course of sodium excretion in the whole group (n-90) during seven days of
l rcMriciton
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A closer look at the data revealed that patients could respond in at least four
different ways to the sudden decrease in sodium intake (figure 2). In group 1
(n = 31) the fall in sodium excretion was consistent with a first order exponential
process, reflected by the fact that sodium excretion fell by approximately 50 % on
each consecutive day until the new staedy state level had been reached. In group 2
(n=10) sodium excretion showed an oscillatory pattern before reaching a steady
state around 55 mmol. In group 3 (n = 32) sodium excretion fell gradually to
approximately 55 mmol/day within three days, but displayed a rise (above 55
mmol) during the following days. Finally, in group 4 (n=17) sodium excretion
remained high during several days of sodium restriction; in this group sodium
balance was attained only after day 5 or not at all.
ss-
group 1
3 4 5 6
Time (days)
ss-
group 2
3 4 S 6
Time (days)
110n
55-
1HH
SI
55-
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2 3 4 s 6
Time (days)
group 4
1 2 3 4 ( • 7 I
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Figure 2. Examples of the sodium excretory patterns in the four groups
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Age and data for sodium and potassium excretion, mean arterial pressure (MAP)
and weight on the second hospital day (first day of sodium restriction) in these four
groups arc shown in table 1. To account for possible stress reactions related to
hospital admission blood pressure data gathered on the first day were ignored.
Blood pressure was slightly different between the four groups, but this was not
statistically significant. As shown in table 2 the observed decline in blood pressure
after seven days of sodium restriction was largest in group 4, whereas it was least
in group 1 (p<0.05). Group 2 and 3 took intermediate positions. The magnitude of
the blood pressure fall after seven days of sodium restriction was not correlated to
initial blood pressure.
Tablt I. Baseline characteristic! after hospital admission in ihe four group*.
Age
(yr«>
UnaV
(mmol)
UkV
(mmol)
MAP
(mm Mi!)
Wcijhl
(kg)
Group 1
37
(18-59)
91
(69-156)
61
(31-109)
116
(94-146)
77
(59-99)
Group 2
40
(30-56)
97
(77-185)
74
(56-106)
124
(109-160)
80
(53-101)
Group 3
32
(28-«7)
94
(69-273)
65
(40-156)
124
(98-179)
85
(58-106)
Group 4
48
(21-70)
100
(70-130)
66
(36-133)
114
(97-141)
79
(54-93)
UnaV-urinary sodium excretion; UkV-urinary polassium excretion; MAP = mein arterial pressure
In all lour groups the greatest fall in blood pressure was seen during the first
three days of sodium restriction.
Along with the different sodium excretory patterns, cumulative sodium balances
also tended to be different between the groups. Group 1 displayed a sodium loss of
36 (-131 to + 152) mmol, whereas group 4 lost 109 (-270 to -48) mmol of sodium.
Again group 2 and 3 look intermediate positions with sodium losses of 64 (-208 to
+ 81) and 84 (-253 to +109) mmol respectively. The difference in cumulative
sodium loss between group 1 and group 4 was statistically significant (p<0.05).
Time course of polassium excretion was comparable in all four groups and
potassium balances after seven days were not different either. In all four groups
weight loss during the study week was approximately 1.5 kg.
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Table 2. Changes in variables in the four groups after seven days of sodium restriction* p<0.05 as compared lo
group I
N a '
balance
(•wol)
bataace
(mmol)
Change
in MAP
(mm Hg)
Weight
loss
(kg)
Group 1
-36
(-131 to +151)
-1
(-197 lo 292)
-3
(-16 to +6)
•1.5
(-3.7 to +1.2)
Group 2
-64
(-208 to +81)
-22
(-161 lo +76)
-6
(-21 to +2)
-1.3
(-4.2 to 0.0)
Group 3
-84 ,;,
(-253 to +109) _,
-21
(-254 to +140)
-8
(-25 to +10)
•1.5
(-3.9 to +0.4)
Group 4
; ; , "109*
,. . , , ; (-270 to -48)
-2
(-392 10 +154)
• 1 0 *
( - 4 2 to + 7 ) • • ;
• 1 . 6
(-4 lo -0.5)
Discussion
Until now, all studies on sodium excretion during modifications of dietary sodium
intake have reported that changes in sodium excretion during restriction mimick a
first-order exponential process*. Moreover, it is generally held that sodium output
matches the new intake within, approximately, four days. If we would have
analyzed our data on sodium excretion for the whole group, we also would have
found a pattern that is consistent with a first order exponential process (figure 1).
However, instead of looking at mean or median values of sodium excretion in the
whole group, we studied the sodium excretory pattern of each patient individually.
In fact, our data suggest that there are at least four different sodium excretory
patterns by which subjects attain sodium balance during sodium restriction.
As patients were admitted to a metabolic ward and since both sodium intake and
urine collections were carefully monitored in each patient we think it is unlikely
that the results can be explained by insufficient compliance of patients. We are not
informed, however, about the reproducibility of the various excretory patterns and,
hence, we cannot ascertain whether a particular pattern has to be considered as an
intrinsic property or as a variable that may change over time. Also, the
(patho)physiological meaning of the different excretory patterns is unclear.
Nevertheless, the differences between the groups suggest that the balance between
sodium-retaining and sodium excretory mechanisms may be affected differently
between subjects, when dietary salt intake changes.
A shift towards continued excretion of sodium, despite restriction, may be
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related to a higher initial body sodium content (as observed in group 4). Indeed,
according to the Strauss-concept, there is a critical level of body sodium, below
which the kidney starts retaining sodium and above which the excess of sodium is
rapidly excreted*. If this is true, we have to assume that patients in group 4 must
have had difficulty in excreting an excess of sodium prior to this study. Perhaps,
these patients resemble the non-modulating or salt-sensitive hypertensive subgroup
that has been described by Hollenberg and coworkers'. Whereas the data from
group 1 suggest that the body, at least in these patients, is able to sense actual
sodium intake and to adapt to that intake gradually, the patterns in group 2 and 3
indicate that sometimes the body has to "seek" the proper sodium output.
Clearly, further research is necessary to elucidate the possible determinants of
these patterns.
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Sodium sensitivity of blood
pressure in hypertensives is
not related to sodium, but
rather to renin
Abstract
Objective
The purpose of this study was to investigate whether a certain degree of sodium-
sensitivity of blood pressure in essential hypertensives during sodium restriction is
related to cumulative sodium loss. >,
Methods
One-hundred and seventeen untreated essential hypertensives were admitted to a
metabolic ward for seven days and put on a sodium restricted diet of 55 mmol/day.
During seven days urinary excretions of sodium, potassium and creatinine were
determined daily along with mean arterial pressure (MAP) and weight. Active
plasma renin concentration (APRC), aldosterone (ALDO), renal plasma flow (RPF)
and plasma volume (PV) were assessed after seven days under steady state
condition. The population was divided into tertiles based on the final changes in
blood pressure after seven days.
Results
Tortile 1 displayed a median fall in MAP of 13 (-42 to -9) mm Hg, whereas in
tertile 2 and 3 a fall of 6 (-9 to -4) mm Hg and a rise of 1 (-3 to +11) mm Hg
respectively, was encountered. Baseline characteristics were comparable between
the tertiles. When tertile 1 was compared to tertile 3 no significant differences
between these tertiles were found with respect to cumulative sodium and potassium
balances and weight losses. On the other hand, APRC levels were significantly
higher in tertile 3 as compared to tertile 1 (22 and 27 mU/1, respectively). RVR
tended to be higher in tertile 3, although this was not statistically significant. Aldo,
RPF and PV were comparable between the tertiles.
Conclusions
In contrast with tertile 1, MAP in tertile 3 is maintained at its original level,
despite comparable sodium losses. In tertile 3. however, levels of renin are higher
compared to the group that is more sodium-sensitive. Therefore, our data suggest
that the degree of sodium-sensitivity of blood pressure in essential hypertensive
subjects is not determined by sodium status, but rather by renin.
26
Introduction «!T
Many studies have addressed the association between blood pressure and sodium
intake. For instance, data from the Intersalt study showed that for every 10 mmol
rise in a population's sodium intake there was an average increase of 0.9 mm Hg
systolic and 0.45 mm Hg diastolic in the population's blood pressure". However, it
is known that people differ in their susceptibility to alterations in dietary salt intake
and that they may respond with widely varying changes in blood pressure. Hence,
the salt-sensitivity concept was developed", though its pathophysiological
significance has been disputed'.
A defect in renal sodium excretion, possibly due to sympathetic overactivity
and/or involvement of the renin-angiotensin-aldosterone system has been suggested
as a potential mechanism of salt-sensitivity* \ Still, inferences about the
determinants of salt sensitivity remain troublesome, not the least because most
authors have dichotomized their study subjects into a salt-sensitive and salt-resistant
group and have used different and arbitrary working definitions of salt sensitivity''.
However, as changes in blood pressure during dietary salt manipulation follow a
Gaussian distribution', it would be more appropriate to deal with salt-sensitivity as
a gradual phenomenon.
In the present study, therefore, characteristics of salt sensitivity were studied in
relation to the degree of blood pressure changes during sodium restriction.
Patients and methods
Patients
Only patients with uncomplicated essential hypertension and an urinary sodium
excretion of more than 70 mmol/day were selected for the present study.
Secondary hypertension had had to be ruled out by routine laboratory examination
and besides essential hypertension no concomitant disease had to be present.
Patients who regularly used non-steroidal anti-inflammatory drugs were excluded.
Antihypertensive treatment, if any, was withdrawn at least three weeks prior to the
study (six weeks in case of diuretics).
The study was approved by the Ethics Committee of the University Hospital and
written informed consent was obtained from all patients.
Study protocol
Patients were admitted to a metabolic ward for 8 days and put on a sodium-
restricted diet containing 55 mmol of sodium and 70 mmol of potassium per day.
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The amount of calories remained constant during the entire study period and was
calculated on an individual basis. Physical exercise was kept constant during the
admission period and smoking was forbidden. Twenty-four hour urine collections
for determination of sodium, potassium and creatinine excretion were started
immediately after admission and continued until discharge. Accuracy of the urine
collections was assessed by creatinine excretion. ,:
Mean arterial pressure (MAP) was measured every hour by Dinamap (Tampa,
Florida) and averaged for each day. In addition, weight was determined daily.
After seven days, when a steady state had been reached, plasma volume (PV;'"I-
labcled albumin), renal plasma flow (RPF; '"I-labeled hippuran), active plasma
renin concentration (APRC; IRMA-method) and aldosterone (ALDO; Coat-a-Count
method) were determined. Blood volume (BV) and renal vascular resistance (RVR)
were calculated.
Based on their blood pressure fall from day 2 until day 7, patients were divided
into tcrtiles. Because of possible stress reactions related to hospital admission,
blood pressures on day 1 were ignored. Differences in characteristics between
(ertiles were analyzed by the non-parametric Kruskall-Wallis test. A statistical
value of p<0.05 was considered significant. Because data were not normally
distributed they are expressed as medians and ranges.
Results
One-hundred and seventeen essential hypertensive subjects with a median age of 47
(18-70) years were studied. Urinary creatinine excretion during the entire study
period averaged 13.8 mmol/24 hour (range 5.0-29.0). After seven days of sodium
restriction changes in blood pressure varied from -42 to +11 mm Hg (median fall:
7 mm Hg). Based on the changes in blood pressure patients were divided into
tcrtiles: tertile 1 displayed a fall in blood pressure of 13 (-42 to -9) mm Hg,
whereas in tertile 2 and 3 a fall and rise in blood pressure of 6 (-9 to -4) and 1 (-3
to+11) mm Hg respectively, were encountered.
Baseline characteristics
Initial levels of blood pressure, sodium excretion and weight were comparable in
the three tertiles and showed the same distribution (table 1). Age was also similar
in the three groups.
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Table 1. Palienl characteristics al baseline.
Age
(yrs)
MAP
(mm Hg)
Weigh)
(kg)
UnaV
(mmol/day)
Tertile 1
47
ao<7)
127
(98-173) / • '
81.4
(54.4-105.9)
130
(71-328)
Tertile 2
4.1
(20-70)
128
(96-156)
80.0
(52.3-104)
137
(73-311)
Tcrtlk 3
52
(18-64)
121
(102-163)
77,9
(52-114.2)
158
(100-291)
MAP-mean arterial pressure; UnaV-urinary sodium excretion
Sodium, potassium and weight losses during sodium restriction
Despite the restriction in dietary sodium, cumulative sodium balance became
positive in several patients who responded to the intervention by an extreme drop
in urinary sodium output. The number of such patients, however, was equal in the
three tertiles. Also, no differences in time-course of sodium excretion between the
tertiles were apparent. Cumulative sodium losses amounted to 72 (-253 to +131)
mmol in tertile 1, 74 (-355 to +132) mmol in tertile 2 and 53 (-307 to +145)
mmol in tertile 3 (figure 1). There were no statistically significant differences in
sodium loss between the tertiles. Weight losses were also comparable between the
tertiles: 1.5 (0 to -3.2) kg in tertile 1, 1.5 (+0.5 to -4.5) kg in tertile 2 and 1.7
(+0.5 to-4.5) kg in tertile 3. Finally, there were no differences between the
tertiles with respect to changes in potassium balance. As shown in figure 2, there
was no correlation between changes in sodium balance and changes in blood
pressure at the end of the study period.
tertile 1 terti1e2 tertile 3
Figure 1. Changes in cumulative sodium balance and blood pressure in fertile* 1. 2 and 3
after seven days of sodium restriction (steady stale condition;
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Figure 2. Changes in blood pressure plotted against changes in cumulative sodium loss after
seven days of sodium restriction
Hemodynamic and hormonal data at steady state (day 7)
Levels of APRC alter seven days of sodium restriction were higher in tertile 2 and
3 as compared to tertile 1. The difference between tertile 1 and 3 was significant
(figure 3). On the other hand, aldosterone levels were not different between the
tertiles after seven days of sodium restriction (figure 3).
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Figure 3. I evels of renin and iklostcronc in temles I. 2 and 3 after seven diys of sodium restriction
(steady state condition)
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Data for renal hemodynamics and volume measurements on day 7 of hospital
admission are given in table 2. Renal plasma flow, renal blood flow, blood volume
and plasma volume did not differ between the tertiles. There was a trend for renal
vascular resistance to increase from tertile 1 to tertile 3, but this was not
statistically significant.
Table 2. Renal hacmodyrumics and blood/plasma volume after 7 days of sodium restriction (steady sUle) volume
RPF
(ml/min)
RBF
(ml/min)
RVR
(units)
PV
(ml)
BV
dull
Tertile I
361
(295-962)
1010
(543-1850)
8421
(1082-15896)
2976
(1990-4006)
5257
(3431-7211)
Tertile 2
563
(317-815)
(572-1455)
8752
(5168-15316)
2990
(1764-4325)
5090
(3090-6775)
Tertile 3
546 • i
(585-905) ,,,,
tsc
(5851551)
9655
(5030-19155)
2873
(2OIM3I4)
5241
(3591-7598)
RPF = renal plasma flow; RBF = renal blood flow; RVR «renal vascular resistance: PV-plasma volume;
BV-blood volume
Discussion
In the present study we divided our patients into tertiles according to the magnitude
of their blood pressure responses to sodium restriction. Whereas tertile 1 displayed
a clear fall in pressure, blood pressure hardly changed in tertile 3. According to
current thinking, therefore, tertile 1 would be classified as salt-sensitive and tertile
3 as salt-resistant. Nevertheless, by carefully monitoring sodium balance we found
that tertile 1 lost the same amount of sodium during restriction as fertile 3.
Moreover, we did not observe a relationship between changes in cumulative
sodium balance and changes in blood pressure.
Our results, therefore, suggest that the degree of blood pressure fall during
sodium restriction is independent from the cumulative sodium loss. Not only was
there no exaggerated sodium loss in tertile 1, also weight loss was comparable
between the tertiles. This further strengthens the idea that the degree of
extracellular volume depletion was similar in the three tertiles. Thus, our data
could not substantiate the idea that salt-sensitivity is associated with defective renal
sodium handling and a disturbed pressure-natriuresis relationship***. On the other
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hand, our results are in keeping with the data of Campese et al., who also were
unable to demonstrate differences in sodium balance between salt-sensitive and salt-
resistant subjects'". In point of fact, most studies failed to demonstrate a significant
relationship between the amount of sodium lost during sodium depletion or retained
during sodium loading and the accompanying changes in arterial pressure".
To determine whether differences in sodium sensitivity across the tertiles were
associated with differences in renal hemodynamics or circulating volume we also
measured plasma volume and renal plasma flow in all patients after seven days of
sodium restriction. Since it was not the purpose of the present study to evaluate
changes in these variables during changes in sodium balance, we deliberately
performed our measurements in steady state. By doing so, we would allow for a
meaningful comparison of the tertiles.
Plasma or blood volume did not differ between the tertiles. Although data on
plasma and blood volume during sodium restriction are scarce, our results are in
accordance with those of Oshima et al., who also found that plasma volume was
not different in salt-sensitive subjects when compared to salt-resistant ones'^.
Therefore, we think that salt-sensitivity is not determined by volume status. Our
data on renal hemodynamics are at variance with those of Fujita et a l / who
reported a higher renal vascular resistance in salt-sensitive subjects, whereas our
data, if anything, suggest that renal vascular resistance tends to be higher in salt-
resistant subjects.
The present study was not designed to investigate the dynamic response of the
renin-angiotcnsin-aldosterone system to sodium restriction. We cannot exclude,
therefore, that the rises in renin and aldosterone were inadequate in patients who
are most salt sensitive.
Our observations on steady state levels of renin, however, are in accordance
with other data, which demonstrated that salt-sensitive subjects have lower renin
levels'. However, despite the fact that renin levels were lower in tertile 1 than in
tertile 3, they were certainly not suppressed. Ishii et al. found that sensitivity of
blood pressure to increased dietary salt intake in hypertensive patients could be
related to altered aldosterone dynamics". Also, other studies reported that patients
with the greatest fall in blood pressure displayed the least rise in renin and
aldosterone. In our hands, however, aldosterone was not related to the degree of
sodium sensitivity. This discrepancy (in aldosterone results) may be explained by
the fact that in the latter studies patients were more sodium depleted, as sodium
diets of 20 mmol and 10 mmol in addition to 40 mg of furosemide were used. By
contrast, our patients consumed a diet of 55 mmol of sodium. It could well be that
differences in aldosterone levels become more marked as sodium depletion is more
severe. We further found that subjects with a higher degree of sodium sensitivity
were of similar age as those who were least sensitive and certainly not older as has
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been suggested in other studies'. -.-i-ur
In conclusion, our data indicate that a greater degree of sodium sensitivity of
blood pressure in hypertensives is associated with lower, but not necessarily
suppressed levels of renin and a tendency towards a lower renal vascular
resistance. Whilst these findings again point to the kidney as the major determinant
of sodium sensitivity, our results do not favor the hypothesis that disturbances in
sodium handling or volume regulation are involved.
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Sodium sensitivity of blood
pressure during sodium
restriction is related to
inadequate activation of renin
during the early phase of
sodium loss
MME Krekels, NC Schaper, PW de Leeuw
(submitted for publication)
Abstract
Objective
The objective of the present study was to explore the interrelationships between
cumulative sodium loss, renin activation and blood pressure changes during sodium
restriction in essential hypertensives. Specifically, we wanted to know whether the
degree of sodium sensitivity of blood pressure depends upon renin activation during
steady state or upon initial renin activation during the first days of sodium
restriction.
Methods
Sixty-seven untreated essential hypertensive patients were admitted to a metabolic
ward for eight days and put on a sodium restricted diet of 55 mmol/day from the
second to the last day. Urinary excretions of sodium, potassium and creatinine
were determined along with mean arterial pressure and weight during seven days.
Besides measurements in steady state condition (after seven days) active plasma
renin concentration, aldosterone and catecholamines were also assessed during the
first three days of sodium restriction.
Results
Analyzable data are available for 55 patients. Both baseline sodium excretion and
the activation of renin during the first three days appeared to be predictors of total
sodium loss after seven days. Changes in blood pressure were not related to
changes in sodium balance, but they were to baseline blood pressure, baseline
norepinephrine and renin activation during the early phase of sodium restriction. In
addition, blood pressure appeared to fall more when the normal relationship
between sodium loss and early (but not late) activation of renin was disturbed.
Conclusion
We conclude that sodium sensitivity of blood pressure during sodium restriction is
linked to a relative unresponsiveness of the renin system during the early phase of
sodium loss rather than to absolute renin levels during steady state.
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Introduct ion i v; .JJ*
Although sodium sensitivity of blood pressure has been the subject of many
investigations, the mechanisms underlying this condition have not yet been
elucidated. Among the potential pathophysiological mechanisms involved are
sympathetic overactivity' \ possibly in conjunction with an increased ratio of alpha-
2 over beta-2 adrenoceptors* and altered sodium handling by the kidney^'. Sodium
sensitivity appears to be related to older age. black race and low levels of renin and
prorenin*". In addition, it has been linked to a blunted rise in renin with sodium
restriction* "'*. However, interpretation of available data is difficult, because in
many of the studies dealing with sodium sensitivity no information is given
regarding changes in body fluid volumes or cumulative sodium balance. Moreover,
little is known about the time course of changes in sodium balance and renin that
determine the final change in blood pressure. This prompted us to study the
interrelationships between changes in cumulative sodium balance, renin and blood
pressure during a period of sodium restriction in more detail. As sodium sensitivity
should be considered as a gradual phenomenon*, we analyzed the data in relation to
the degree of blood pressure changes rather than on the basis of an arbitrary cut-off
point.
Methods
Patients
Sixty-seven patients with essential hypertension were included in this study after
having given written informed consent. Secondary hypertension had been ruled out
by routine clinical and laboratory investigations and antihypertensive medication, if
any, was stopped at least 3 weeks prior to the study. None of the patients had been
treated with diuretics within twelve months before the start of the study. To be
eligible, supine diastolic blood pressure had to be above 95 mm Hg and 24-hour
urinary sodium excretion had to be at least 70 mmol on multiple occasions. In
addition, serum creatinine concentration had to be below 120 /imol/l.
Protocol
All patients were admitted to a metabolic ward for 8 days and kept on a diet
containing 55 mmol of sodium per day; potassium intake was fixed at 70 mmol per
day. The diet was designed by the hospital dietitian and adjusted to the subjects'
caloric intake. Meals were prepared by the metabolic kitchen. Since blood pressure
may show a non-specific fall on the day of admission, the study proper was started
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on the second hospital day. •••••• > • • !
Twenty-four hour urine collections for determination of sodium, potassium and
creatinine were started immediately after admission and continued throughout the
study period. Cumulative sodium balances were calculated from the first day of
dietary restriction onwards. Completeness of urine collections was verified from
creatinine excretions. For each patient, data from a 24-hour urinary collection were
accepted for analysis only when creatinine excretion in that collection deviated by
no more than 5% from the average creatinine excretion during the entire study
period in that patient. During daytime mean arterial pressure (MAP) was measured
every hour by Dinamap (Tampa, Florida) and averaged for each day. In addition,
weight was determined daily. During the first three days of sodium restriction
blood was drawn at 8.00 a.m. for the measurement of active plasma renin
concentration (APRC), angiotensin II (Angll), aldosterone (ALDO) and
catecholamines. After seven days, when a steady state condition had been reached,
these variables were assessed once more. APRC was determined by the IRMA
method", whereas ALDO was measured by radioimmunoassay"\ Angll was also
measured by radioimmunoassay after extraction of plasma'^. Catecholamines
(norcpinephrine and epinephrine) were assessed by a radioenzymatic (COMT)
method using HPLC for separation of radioactive products'*.
Statistical analysis
Results are expressed as means and standard deviation. Regression analysis was
applied to detect associations between variables. Associations that were found to be
significant in univariate analysis were grouped together and tested again in a
multivariate analysis. A sliding mean analysis technique was used to explore the
relationship between changes in blood pressure and certain aspects of volume
control. A p-value <0.05 was considered to denote statistical significance.
Results
In twelve of the sixty-seven patients at least one of the seven urine collections was
incomplete, making it impossible to calculate in these subjects cumulative sodium
losses after the dietary intervention. These patients were therefore excluded from
analysis. Urinary creatinine excretion averaged 14±4 mmol/24 hour for the entire
study period. Baseline characteristics of the remaining 55 patients are presented in
table 1. The study population consisted of 36 men and 19 women who were all of
European descent. Mean age was 41 years with a range from 20 to 67 years. At
the start of the study blood pressure was. on average, in the hypertensive range but
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three patients proved to have normal blood pressure at that time. Mean 24-hour
urinary sodium excretion on admission was 121 mmol, but varied over a wide
range. In six subjects initial sodium excretion was below 70 mmol per 24 hour. In
the whole group baseline concentrations of catecholamines, renin, angiotensin II
and aldosterone in plasma were normal, but in eleven of the 55 patients (20%)
renin levels were low. These low-renin patients did not differ from the others with
respect to age, weight, initial blood pressure and baseline sodium excretion.
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Table 1. Patient characteristics at baseline -
Mean ± SD Range
Age (years)
Male/female
Weighc (kg)
Systolic pressure (mmHg)
Diasiolic pressure (mmHg)
Heart rate (bpm)
UnaV (mmol/day)
UkV (mmol/day)
UcreatV (mmol/day)
Norepinephrine (nmol/l)
Epinephrine (nmol/l)
APRC (mU/l)
Angll (pmol/l)
Aldo (pmol/l)
4 3 ± l l
80±14
161 ±22
IO7±11
79*9
121 ±56
56±21
14.1 ±4.2
1.65 ±0.80
O25±O.I8
I7.9±9.l
5.7±5.2
304 ±169
36/19
22-«7
52114
106-212
85-130
41-97
49-274
14-105
7.0-27.0
0.15-3.59
0.02-1.03
nd-41.0
nd-15.0
120-875
UnaV = Urinary sodium excretion: UkV = Urinary potassium excretion: UcrealV- Urinary crcaunine excretion:
APRC = Active plasma renin concentration: Angll = Plasma angiotensin II: Aldo = P1asma aldmtcrone: nil mil
delectable
Cumulative sodium balance
Twenty-four hour urinary sodium output amounted 121 ±56 mmol at the start of
the study, but fell gradually, as expected, during the first few days of dietary
restriction. A new steady state where sodium output again matched intake generally
was reached by the fourth day, but time courses varied from three to six days.
While cumulative sodium balance became negative in the majority of patients, in
10 of them (18%) actually a positive balance was found at steady state. The latter
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was due to an extreme fall in urinary sodium output upon institution of the diet.
In the whole group cumulative sodium balance fell by an average of 112 mmol
(range -455 to +155 mmol), which was associated with a mean weight loss of
1.8 kg (range -4 to 0 kg). The total amount of sodium excreted over seven days
was not related to age nor to initial weight or blood pressure. However, as shown
in figure 1 cumulative sodium loss was positively related to sodium excretion on
the first day of salt restriction (y = 1.6x-77; r=0.68; p<0.001). In addition, an
inverse correlation was found between renin concentration on the first day of the
intervention and cumulative sodium loss (y = 203-5.lx; r = -0.36; p<0.01) . In the
multivariate analysis, however, only initial sodium excretion remained as a
significant determinant of total sodium loss.
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KIgurr I. Scanerpkil showing (he relationship between sodium excretion on (he first day of
dietary restriction and cumulative sodium loss after one week
Ncurohumoral responses
Renin concentrations rose appropriately during sodium restriction but individual
renin responses varied widely: from a fall of 17 mU/1 to a rise of 47 mU/1 after
three days and from a fall of 12 mU/1 to a rise of 62 mU/1 after one week.
Changes in renin proved to be independent from baseline levels. The early renin
response (i.e. the change in renin from the first to the third day) appeared to be
inversely related to age (y= 19.7-0.35x; r = -0.36; p<0.01), whereas the final
response (the change in renin after one week) was not. When patients were
classified according to their renin response on the third day, those with the least
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response had the greatest increase in renin from day 3 to day 7. while a slight fall
in renin was seen in those patients with the largest increment in renin during the
first three days.
Both on the third and on the seventh day renin responsiveness was inversely
related to the pre-intervention mean arterial pressure (y = 36-0.26x; r = -0.45;
p<0.001 and y=65-0.45x; r = -0.39; p<0.05 respectively). Although the early
renin response was not related to initial sodium excretion, a positive relationship
was found between sodium excretion on the first day and renin levels on the last
(y=0.l lx-5.8; r=0.44; p<0.05). When the various factors were tested in a
multivariate analysis model, age and pre-intervention MAP remained as the only
independent determinants of the early and final renin response respectively. In
other words, a higher age and a higher blood pressure blunted the changes in renin.
By and large, Angll and ALDO followed the same patterns as those observed for
renin. There were, indeed, very close relationships between changes in renin and in
Angll on the one hand and between changes in Angll and in ALDO on the other.
In contrast to the alterations in the renin-angiotensin-aldosterone system,
catecholamine concentrations remained stable throughout the study period.
Blood pressure responses
After seven days of sodium restriction changes in MAP varied from -49 to +6 mm
Hg (mean fall 16 mm Hg). Blood pressure fell by more than 10 mm Hg in 36 of
the 55 patients (65%). Changes in blood pressure were not related to age, initial
sodium excretion or renin on day 1. However, significant inverse relationships
were observed between the final change in MAP and MAP on the first day (y = 31 -
0.37x; r = -0.53; p<0.0001) and between the change in mean arterial pressure and
norepinephrine levels on day 1 (y = -5.5-5.9x; r = -0.46; p<0.001). Both factors
remained also significant in the multivariate analysis, indicating that a higher blood
pressure and a higher level of norepinephrine before the intervention were
associated with a greater fall in pressure.
Interrelationships between changes in sodium balance, renin and blood
pressure
When patients in whom renin was unchanged or had fallen on the third day of
sodium restriction were compared to those in whom renin had risen by that time,
the former group displayed a significantly greater sodium output on the third and
fourth day of the dietary restriction but not on any of the other days (figure 2).
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Figure 2. Line graph showing the change in urinary sodium output with time in patients with
a normal (open circles) or a blunted (closed circles) early renin response
Moreover, the early renin response appeared to be a important predictor of total
sixlium loss as a significant inverse relationship was found between the degree of
renin activation on the third day on the one hand and cumulative sodium loss after
seven days on the other (y=131-3.5x; r=-0.30 p<0.05; figure 3a). With respect
to the final renin response after seven days, however, this relationship had reversed
(y = 3.6x + 65; r = 0.40; p<0.05). Multivariate analysis proved sodium excretion on
the first day (p<0.00l) and both the initial (p<0.001) and the final (p<0.01)
renin response to be independently related to total sodium loss with an overall
explanatory power of 70%. Also in this multivariate analysis absolute renin levels
on the first day were not independently related to cumulative sodium loss.
As illustrated in figure 3b the change in mean arterial pressure that had occurred
at the end of the study period appeared to be significantly related to the early rise
in renin (y=0.4x-l7.4; r = 0.40; p<0.005). No such relationship, however, was
found with the final change in renin. Since changes in blood pressure were also
related to bkxxl pressure and norepinephrine levels on the first day (see above), we
performed multivariate regression analysis to evaluate the relative importance of
these factors. In tact, all three factors turned out to be significant and independent
predictors of the final change in pressure with an explained variance of 46%.
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Figure 3. Scaiterplots showing the relalionship beiwecn the change in renin during ihc first
three days of sodium excretion on the une hand and cumulative sodium loss (a:
upper panel) or the final change in blood pressure (h: lower panel) after one week
on the other hand
Although both cumulative sodium loss and the final change in blood pressure
were related to the early rise in renin sodium losses and blood pressure after one
week were not related to each other. Therefore, we tested whether the ultimate
change in blood pressure was correlated with the "strength' of the relationship
between early renin activation and sodium loss. To this end we applied the
technique of moving averages. Patients were ranked according to the magnitude of
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their blood pressure change and starting with the lowest value the correlation
coefficient for the relationship between the early rise in renin and the final change
in sodium balance was calculated for the first twenty patients. Subsequently, the
same relationship was calculated after adding the next higher data point while
deleting the first data point and so forth". Results of this analysis are depicted in
figure 4. The data show that as the fall in pressure is less, the relationship between
early renin responsiveness and cumulative sodium loss at the end of the study
becomes stronger and statistically significant. Conversely, a larger fall in pressure
is associated with the lack of a significant relationship between the early renin
response and sodium loss.
).75n
0.50-
| 0.25H
0.00
p<0.05
-30 -20 -10 0
Change in blood pressure (mm Hg)
Figure 4. Scanerplnt showing Ihe relationship between Ihe change in blood pressure after one
week ol stxlium restriction and the correlation coefficient (sign omitting) that
describes the strength ol the relationship between early renin activation and final
sodium loss. Kach point represents the average of twenty patients and differs from
the preceding or succeeding point by only one observation
Discussion
The mechanisms whereby sodium restriction lowers blood pressure in salt-sensitive
individuals are still poorly understood. Although some investigators have suggested
that salt-sensitive subjects differ from salt-resistant ones in their ability to achieve
sodium balance on a low salt diet, others have failed to demonstrate consistent
differences in sixlium balance between salt-sensitive and salt-resistant patients***'.
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Moreover, at least two groups have shown that alterations in blood pressure during
dietary salt restriction are independent from changes in cumulative sodium loss" "\
However, in these studies a rather rigorous protocol to achieve sodium depletion
was followed, including the administration of furosemide. Thus, while these results
may be indicative for a state of true volume depletion, they do not necessarily
reflect the relationship between volume and pressure under less extreme conditions.
In the present study we adopted a more liberal approach. After admission to
hospital all patients were put on a mildly sodium restricted diet (55 mmol/day)
which probably better reflects real life situations. All patients had continued iheir
habitual diet until the intervention, because we deliberately wanted to achieve a
wide variation in cumulative sodium losses at the end of the dietary period. Not
unexpectedly, we found that the total amount of sodium lost during the dietary
period correlated with urinary sodium excretion on the first day of the study. In
other words, changes in cumulative sodium balance following institution of a
sodium restricted diet are to a large extent determined by the level of salt intake in
the preceding period. Nevertheless, despite the large splay in cumulative sodium
losses, we failed to find a relationship between changes in sodium balance and
changes in blood pressure. In this respect our data corroborate and extent those
from the earlier studies" *\
When changes in blood pressure during sodium restriction are not determined by
the degree of volume loss, other factors must be responsible. Since the renin-
angiotensin-aldosterone system is involved in both hemodynamic regulation and in
volume homeostasis, we took multiple blood samples during the study to assess the
responsiveness of this system. Contrary to others* we could not find a relationship
between baseline renin and final changes in blood pressure. However, our data do
show some linkage between the degree of renin responsiveness and the magnitude
of blood pressure changes. Although not very impressive, a positive relationship
was observed between the early renin response (i.e. during the first three days of
sodium restriction) and the difference between final and initial blood pressure,
indicating that a greater renin response during the first few days of sodium
restriction was associated with a lesser fall in pressure (figure 3b). In principle (his
confirms the data from others who have also shown that salt sensitivity is linked to
a blunted responsiveness of the renin system'-^22.24-2* Interestingly, though, our
data also demonstrate that final changes in renin (i.e. after one week) do not
correlate anymore with changes in blood pressure. Given the fact that salt
sensitivity is not limited to subjects with suppressed renin, but also occurs among
people with normal renin levels, our findings seem to suggest that an abnormal
dynamic behavior of renin during the early phase of sodium loss rather than steady
state levels of renin is linked to the phenomenon of salt sensitivity. Since an
abnormal renin response is more likely to occur in patients with low renin levels or
45
elderly patients, it is not surprising, therefore, that salt sensitivity is more prevalent
in these groups.
The question now arises why hormonal responses that occur early during sodium
restriction have such an impact on blood pressure a few days later. Although we
can only speculate about the answer, it is noteworthy that the early renin response
more or less coincides with the period that the organism is 'seeking' a new steady
state to match urinary sodium excretion to sodium intake. Interestingly, we found
an inverse relationship between early changes in renin and total sodium loss after
one week. Thus, the more renin rises during the first few days of sodium
restriction, the less sodium is lost. On the other hand, a positive association was
found for final changes in renin and total sodium loss. Our explanation for these
findings is as follows: when sodium intake is suddenly decreased, cumulative
sodium balance falls in proportion to initial sodium intake. The greater the
decrement in sodium balance, the more renin eventually rises. Thus, renin levels at
the end of the dietary period seem to be dependent on the amount of sodium loss
rather than the other way around. However, there appears to be a profound
interindividual variation in the speediness of the renin response. As our data show
(figure 2), a brisk renin response during the early days apparently limits the final
sodium loss. As a consequence further stimulation of renin will be slowed down
which, indeed, is exactly what we found. In patients with a more sluggish early
response, on the other hand, we found a more pronounced rise in renin from day 3
to day 7 suggesting that the ongoing sodium loss finally enhanced renin release. As
a corollary of these observations one would be inclined to conclude that a greater
initial stimulation of renin is associated with both lesser volume depletion and a
lesser full in pressure and that, therefore, volume and pressure changes ought to be
correlated. However, as stated above, such a correlation could not be detected in
our data.
In an attempt to put these observations into better perspective we stretched the
analysis of our data a little further by exploring the dynamic relationship between
the fall in pressure on the one hand and the volume-renin connection on the other.
To this end we plotted the correlation coefficient that described the relation
between the early renin response and the final change in cumulative sodium balance
as a function of the fall in blood pressure using a sliding mean analysis technique.
As the plot in figure 4 clearly shows, there is a tight and statistically significant
relationship between initial renin stimulation and sodium loss in the patients in
whom blood pressure falls only slightly. However, a progressively greater drop in
pressure is associated with uncoupling of this renin-sodium relationship. These
observations may now provide an explanation for the lack of a relationship between
changes in cumulative sodium balance and changes in blood pressure. For the same
decline in cumulative sodium balance the change in blood pressure may not depend
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so much upon whether renin rises or not but upon whether renin rises fast enough
as a function of sodium loss. Perhaps renin activation during salt restriction serves
a dual purpose: in the first place it is needed to conserve sodium and maintain body
sodium stores within acceptable limits. At the same time, however, the rise in
renin causes the pressure-natriuresis curve to be shifted to the right in order to
keep the equilibrium point at the same pressure level" "'"*. Once a new steady state
has been attained, the role of circulating renin may become less important as
compared to other mechanisms, e.g. intrarenal renin. This would also explain why
some investigators failed to find an association between renin and salt
sensitivity"*.
The data from the present study do not allow to make inferences about the
causes of a disturbed renin-volume relationship. According to our analyses, higher
age, a higher initial blood pressure and higher norepinephrine levels may all play a
part but further studies are needed to explore this. Volume expansion at the start of
the study could also be involved but is less likely as in an earlier study we did not
find a relationship between the degree of sodium sensitivity and plasma volume".
In conclusion, we have shown that the degree of sodium sensitivity during
sodium restriction is not solely determined by changes in cumulative sodium
balance, but rather by a complex interplay between sodium loss and early (but not
late) renin activation. In our view, it is not a suppressed renin system that is related
to salt sensitivity, but rather the fact that the system is relatively fixed.
Accordingly, it is our opinion that studies on the pathophysiology of sodium
sensitivity of blood pressure should focus more on dynamic processes taking place
early during dietary intervention rather than on differences at steady slate.
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Dissociation between the renal
effects of angiotensin I and II
in sodium-restricted normal subjects
MME Krekels, W Spiering, NC Schaper, AJHM Houben,
PW de Leeuw
(submitted for publication)
Abstract ' ' ^
Hum
Objective
In the present study we compared the systemic and renal effects of equimolar doses
of Angiotensin I (AngI) and Angiotensin II (AngH), in order to determine whether
the effects of AngI can be fully explained by conversion of AngI into Angll in the
plasma compartment.
Methods
Ten healthy volunteers whom were in balance on a sodium-restricted diet were
studied on two separate occasions during which, in random order, infusions of
human AngI or Angll were given in stepwise increasing doses of 0.3, 1 or 3
pmol/kg.min. Mean arterial pressure (MAP), heart rate, effective renal plasma
flow (FRPF), glomerular filtration rate (GFR), renin (APRC), AngI, Angll,
aldosterone (Aldo) and catecholamines were assessed at baseline, after each dose of
AngI or Angll and thirty and sixty minutes after discontinuation of the Angl/Angll
infusion.
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Results
The rise in AngH was significantly lower during the AngI infusion than during the
Angll infusion (p<0.05). The increments in MAP and Aldo and the decrease in
GFR, however, were comparable during both the infusion regimens. In the kidney,
on the other hand, the fall in APRC and ERPF during the Angll infusion exceeded
those during AngI (p<0.05). After cessation of the Angl/Angll infusion, the Angll
concentrations returned to baseline as did MAP, ERPF and Aldo. Only renin
remained significantly inhibited (p<0.05). Catecholamines did not change during
any of the experiments.
Conclusions
Our data suggest that the effects of AngI on blood pressure and aldosterone release
may be brought about by Angll, formed, at least partly, from the AngI at tissue
sites. However, due to a low capacity of the kidney to convert AngI, the renal
effects of AngI are less prominent than those of Angll. The longer-lasting
inhibition of renin after cessation of the Angl/Angll infusion points towards
accumulation of Angll in the kidney.
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Introduction ;.>
Conversion of angiotensin I (AngI) into angiotensin II (Angll) by angiotensin-
converting enzyme (ACE) in tissues other than the lung may contribute to
circulating levels of Angll'"*. Recently, Admiraal and coworkers demonstrated
conversion of arterially derived AngI into Angll in the vascular bed of the forearm
and leg, while they found only little evidence for conversion in the renal vascular
bed*. The latter is in keeping with observations in the isolated perfused rat kidney
showing that the AngI dose had to be 50 times higher than that of Angll to obtain
equipotent vasoconstrictor effects'. These data, when added to the faci that Angll is
very efficiently extracted from the circulation by the kidney*"'', and possibly
sequestrated within that organ'*, may lead to the hypothesis that also in human
kidneys the effects of circulating AngI are less potent than those of circulating
Angll. Such a difference in Angl/II effects does not necessarily apply to other
vascular beds where, as opposed to the situation in the kidney, the conversion of
AngI into Angll may be more pronounced'. If on the other hand, all circulating
AngI would be converted on a 1:1 molar basis into Angll in the plasma
compartment before it reaches the renal vascular bed, the functional renal
(hemodynamic) responses to AngI should be comparable to those of Angll.
These two opposing possibilities prompted us to study the effects of equimolar
doses of AngI and Angll on the kidney. Both peptides were infused intravenously
in order to allow conversion of AngI into Angll in plasma. A second objective of
the study was to explore whether after cessation of the infusions the time course of
the dissipation of the Angl/Angll effects on the kidney was congruent with the time
course of the fall in plasma Angll. A discrepancy between these time courses could
point towards accumulation of angiotensins in the kidney.
Subjects and methods
Ten healthy normotensive volunteers with a mean age of 49±2 (mean±SEM)
years and a body surface area of 1.76±0.06 m* were included in this study. The
protocol was approved by the Hospital Ethics Committee and written informed
consent was obtained from all participants. Each subject had a medical history
taken and underwent a physical examination. Routine laboratory tests were carried
out before the start of the study.
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Protocol
During one week subjects were put on a moderate sodium restricted diet of 55
mmol/day; potassium intake was 80 mmol/day. Compliance with the diet was
checked by measuring sodium output in 24-hour urine collections obtained during
the last three days of the study period. Completeness of urine collections was
inferred from the concurrent creatinine excretion. Subjects refrained from smoking
and alcohol; caffeine and caffeine-like substances were also forbidden on the study
days. All volunteers were studied after an overnight fast in the morning of the last
two days of the dietary period.
On these days two different experiments were conducted according to a
randomized double-blind study design, where except for the infused substance
(AngI or AngH), experimental conditions were similar on the two days. Studies
started at 8.00 a.m and subjects remained supine during the entire session. In both
arms an antecubital vein was cannulated with a 20 G cannula: the one in the right
arm was connected to a 3-way tap for the infusion of Angl/II and P-aminohippu-
rate/inulin, whereas the one in the left arm was used for blood sampling. Subjects
consumed 200 ml of water every hour, to ensure diuresis, until the last blood
samples had been drawn. After a two-hour equilibration period, necessary to reach
steady state plasma concentrations of PAH and inulin, stepwise increasing
equimolar doses of either human AngI or human AngH (Clinalfa AG, Laufelfingen,
Switzerland) were administered. Infused doses were 0.3, 1 and 3 pmol/kg.min.
Each infusion step was continued for 30 minutes. Thereafter, the infusion was
stopped and subjects were followed for another hour. The infusion rates were
chosen on the basis of data from the literature and from earlier experiments
performed in our laboratory.
Study variables were assessed and blood was drawn at baseline, after each dose
of AngI or AngH and thirty (t=120) and sixty (t = 150) minutes after cessation of
the Angl/Angll infusion. Blood samples were drawn for measurement of PAH,
inulin, hematocrit, and plasma levels of AngI and II, active plasma renin
concentration (APRC), aldosterone (Aldo) and catecholamines. Moreover, mean
arterial pressure (MAP) and heart rate (HR) were determined.
Methods
MAP and HR were measured by a semi-automatic oscillometric device (Dinamap
Vital Signs Monitor 1846. Critikon, Tampa. FL, USA). Renal hemodynamics, i.e
effective renal plasma flow (ERPF) and glomerular filtration rate (GFR) were
measured as the clearance of PAH (PAH: aminohippurate sodium; MSD, West
Point. PA, USA) and inulin (Inutest, Laevosan Gesellschaft. Linz. Austria)
respectively, using the continuous infusion method". Both variables were corrected
for body surface area and expressed as ml/min. 1.73m-. Effective renal blood flow
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(ERBF) was calculated using the formula: ERPF/O-hematocrit). Filtration fraction
(FF) was calculated as GFR/ERPF. Renal vascular resistance (RVR) was calculated
according to the formula: (MAP/ERBF)»80.000. ,
Active plasma renin concentration (APRC) was measured by the IRMA-method
(Nichols Institute Diagnostics. Wychen, The Netherlands) with an intra-assay
coefficient of variation (CV) of 2.9% and an inter-assay CV of 7.6%'*. Angll was
determined by radio-immunoassay (RIA) following Ph Phenyl column extraction
(Amersham Int., Amersham, UK; intra-assay CV 4.6% and inter-assay CV
7.7%)". Aldosterone was assayed by means of a solid-phase protein binding RIA
(Diagnostic Products Corporation, LA, USA; intra-and inter assay CV 4.3% and
6.7%, respectively)". PAH (intra-assay CV 4.2%, inter-assay CV of 7.3%) and
inulin (intra-assay CV 4.5%, inter-assay CV 8.1%) levels were measured
spectrophotometrically"•". Norepinephrine (intra-assay CV 4.5%, inter-assay CV
8.1%), epinephrine (intra-assay CV 4 .1%, inter-assay CV 8.6%) and dopamine
(intra-assay CV 3.9%, inter-assay CV 7.1%) were assessed by a sensitive
fluorimetric method, in which catecholamines are concentrated from plasma by
liquid-liquid extraction and derivatized with a selective fluorescent agent prior to
chromatography "\
For each hormone, all samples from the same individual were assayed in a single
run. , . . . . . .
Data analysis
Prior to statistical testing logarithmic or square root transformation of the data was
performed, when appropriate. For each individual the difference in plasma Angll
concentrations caused by the Angll infusion and those after the AngI infusion was
calculated. Subsequently we tested, using confidence intervals (CI), whether these
differences deviated significantly from zero.
To avoid the statistical problems which are inherent to the analysis of serial
measurements", we applied summary statistics (overall mean or median) to assess
differences in the other variables between the AngI and Angll infusion regimens.
To answer the main study question, the period from t=0 until t = 90, coinciding
with the angiotensin infusions, was analyzed separately. To determine whether after
cessation of the Angl/AngH infusion variables had returned to baseline, we tested
whether at the end of the experiment (t= 150) changes in variables differed
significantly from zero.
Results are expressed as means .+. SEM. A p-value of less than 0.05 was
considered significant.
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After five days of sodium restriction (55 mmol/24 hour) all subjects were in
sodium balance (sodium excretion: 53.+6 mmol/24 hour), while potassium
excretion averaged 58jf8 mmol/24 hour. -
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Plasma levels of AngI and AngI I ' - l
At baseline plasma levels of both AngI and AnglT were comparable on the two
study days (table 1). Changes in plasma AngI and Angll are depicted in figure la
and lb. Angll increased during both infusions, but the increment was significantly
greater during the Angll than during the AngI infusion (figure la). Levels
increased by 40±9 pmol/l during the Angll infusion as opposed to only 21+4
pmol/1 during the AngI infusion (p<0.05). Sixty minutes after discontinuation of
both infusions plasma Angll had returned to baseline.
No differences in responses of plasma AngI were observed between the AngI
;incl the Angll infusion. During the two infusions plasma AngI declined by 14±3%
and 14±5% respectively (figure lb). Sixty minutes after discontinuation of the
Angll infusion, AngI levels were still significantly suppressed by 22 ±9%
(p<0.05). In contrast, AngI levels had returned to baseline after stopping the AngI
infusion.
Table I. Hormonal ruwline dan (meirmSEM)
AngI infusion Angll infusion
APRC (ml I/I) 2412 27 ±3
AngI (pmol/l) 91 ±6 86±7
Angll (pmol/l) 14±2 14±2
Aldo (pmol/l) 209 ±36 . 254 ±44
F.pi (nmol/l) 0 08±0.0l 0.08±0.0l
Norepi (nmol/l) 115 ±0.20 1.10±0.23
Dop» (nmol/l) O.29±O.O5 0.23±0.02
APRO-«tnvc plasma remn concentration. Aii^l =>an£>otcnsin I: Angll«angKXensin I I ; AMo = akJosterone;
Fpi«epinephniw; Norepi -norcpincphrine; Dopa = Dopamine
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Figure 1b. Changes in plasma Angl concentrations (pmol/1). Angkuensin I (closed dots),
Angioiensin I I (open dots). #p<0 .05 compared 10 baseline
Blood pressure and heart rate
Baseline MAP and HR were comparable on the study days (table 2). Both
angiotensin infusions increased MAP to the same extent: by 15;+3 mm Hg during
AngI infusion and by 14jf5 mm Hg during AngH infusion (figure 2). No
statistically significant differences could be detected for the responses in MAP
between the two infusions. At the end of both experiments MAP did not differ
anymore from baseline levels. ^ , , ,^^, , . .
HR remained virtually unchanged during all experiments. . *
Table 2. HcmodynamK baseline data (means ±SEM)
AngI infusion AngI I infusion
MAP (mm Hg)
MR (bpm)
BRPF (ml/mm I 73m")
OFR (ml/min.l.73m')
FF<%)
RVR (units)
9O±3
65±3
431 ±54
101 ±10
0.25 ±0.01
11639+1728
86±3
65±2
423 ±58
102 ±10
0 25 ±0.01
11923 + 1735
Angl~angmlen*in I; Angll-angintensin II; MAP-mein arterial pressure: HR = heart rale: ERPF"effective renal
plasma (low; OCR - glnmerular filtration rate: FF-filtnlion fraction; RVR-renal vascular resistance.
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Figure 2. Changes in mean arterial pressure (mm Hg). Angwicnsin I (closed dots).
AngKiiensin II (open dots)
Renal responses
Baseline renal hemodynamic data were not different on the two study days
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(table 2). Changes in ERPF during the infusions are depicted in figure 3. AngH
caused a significantly greater fall in ERPF than AngI which was most pronounced
at the highest infusion rates (17±4% versus 7±4%; p<0.05). Sixty minutes after
either angiotensin infusion ERPF did not differ anymore from baseline. \:K*n/jjg
GFR fell slightly during both infusions but responses to AngI and to AngTI were
comparable (data not shown). Changes in FF during AngI I infusion tended to
exceed the response to AngI, but the difference between the two infusions just
failed to reach statistical significance (17±5% versus 11 ±5%; p=0.07). At
t= 150, FF was not different from baseline on either infusion day.
The increment in RVR amounted 4377±969 dynes.sec/cm^ when Angll was
infused versus 2845 ±584 dynes.sec/cm' during the administration of AngI. This
numerical difference in response was, however, not statistically significant. In
addition. RVR was not different from baseline sixty minutes after cessation of the
AngI/Angll infusion (data not shown).
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Figure 3. Changes in effective renal plasma flow (ml/min. 1.73m'). Angiotemin I (closed
dols). Angiotensin II (open dots). *p<0.05 compared helween (he inlusiom
Hormonal responses
Hormonal data at baseline are given in table 1. Responses in APRC during the two
infusions are shown in figure 4a. APRC fell during both angiotensin infusions but,
on average, the percentage fall in APRC inflicted by the Angll infusion was
significantly greater than that due to AngI (33±5% versus 21 ± 3 % ; p<0.05). At
the end of the experiment (t= 150), APRC was still significantly suppressed after
both substances (p<0.05).
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As illustrated in figure 4b, Aldo concentrations rose to the same extent during
the AngI and Angll infusions, by 222±65% and 201 ±93% respectively (n.s).
Aldo levels fell again after discontinuation of the infusions and did not differ
anymore from baseline concentrations at t= 150. IMH i raioign
Catecholamines did not change significantly during either angiotensin infusion.
«/*•
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In the present study we compared the systemic and renal effects of equimolar doses
of AngI and AngH. As the functional responses to both angiotensins may be
influenced by dietary sodium, we studied the effects of Angl and II in subjects,
who were in balance on a low sodium diet. Moreover, we infused |He'|-AngI and
II, which are exact replicates of the endogenous neptides. To minimize carry-over
effects the different infusions were given in random order and on separate days.
We anticipated that if, on a molar basis, there was a 1:1 conversion of Angl into
Angll in the plasma compartment, the hemodynamic and humoral effects of the two
peptides should be similar. If, on the other hand, the effects of Angl would be less
prominent than those of Angll there would likely be insufficient conversion, either
in plasma or at the tissue level. In particular, this would be relevant for the kidney
where conversion of arterially delivered Angl is thought to be very low, if at all
existent*.
One important result of the present study is that plasma Angll rose significantly
less during the Angl than during the Angll infusion. Our data, therefore, could
point to incomplete conversion of Angl into Angll, at least in the plasma
compartment. However, since the concentrations of Angl remain in the picomolar
range, which is well below the Km of ACE", it is unlikely that saturation of ACE
is responsible for the lesser increment in Angll levels after the Angl infusion.
Moreover, with incomplete conversion one would expect some accumulation of
Angl in plasma, which clearly was not the case. An alternative explanation for our
findings could be that part of the infused Angl was rapidly metabolized by
angiotensinases, either in plasma or in tissues''', thus leaving less Angl available for
conversion. Although we cannot exclude this possibility, there are some striking
features in our data that makes us think otherwise. Indeed, the rises in blood
pressure and in plasma aldosterone, two well-known biological sequelae of an
increase in Angll, were remarkably similar during the Angl and the Angll
infusion. This suggests that the vascular wall and the adrenal cortex, as two of the
major target tissues for the renin-angiotensin system, were facing similar Angll
concentrations on both occasions. The lesser increment in plasma Angll
concentrations after the Angl infusion could now be explained by tissue uptake of
Angl and local conversion of this peptide into Angll. Since the rise in Angll was
approximately 20% less during Angl than during Angll infusion, we would have to
assume that about one-fifth of the administered Angl was converted at the tissue
level. This fraction could even be higher if, after local conversion, the formed
Angll would be released into the circulation.
Our study further shows discordant renal responses to Angl and Angll. In fact,
the fall in ERPF during infusion of Angll was about twice as great as that during
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AngI infusion. In addition, AngI was less effective than Angll in suppressing renin.
If our hypothesis about tissue uptake of AngI and local conversion is correct, the
renal data point towards some disturbance of this mechanism in the kidney.
Enhanced degradation of AngI in the kidney or a reduced capacity of this organ to
convert AngI or both could all explain these findings. The group of Schalekamp
has repeatedly shown that the kidney is not an important conversion site of
aricnally derived AngI but mainly metabolizes this peptide*•'-'\ Experiments in
isolated perfused rat kidneys have also provided evidence that renal conversion of
AngI is only limited\ Data from experimental animals further suggest that higher
renin levels, such as may occur during sodium restriction, are associated with
reduced ACE-activity in the kidney'". If such a mechanism is also operative in
man, (his may have precluded renal conversion of AngI even more.
If there is only minimal conversion of AngI into Angll within the kidney, the fall
in ERPF and in renin which were seen during the AngI infusion are most likely
due to the effect of Angll that was formed in plasma and/or at extrarenal tissue
sites before it reached the kidney.
As far as blood pressure, aldosterone and ERPF are concerned, variables had
returned to baseline one hour alter the infusions had been stopped and plasma
Angll had fallen again to pre-infusion levels. Thus, with respect to these variables
no dissociation between plasma levels of Angll and its physiological effects were
seen. However, with respect to renin such a dissociation did occur as renin was
slill suppressed one hour after cessation of the AngI or Angll infusion. The fall in
renin may be attributed to short-loop feedback suppression by Angll*'".
Apparently, this suppressing effect on renin is longer-lasting than the other effects
of Ang.II. A possible explanation for this discrepancy may be that Angll has
accumulated in the kidney'''".
During Angll infusion plasma levels of AngI declined significantly. This is in
keeping with the data of Menard and coworkers'\ who also observed a fall in AngI
during Angll infusion. Vos and associates even found a decrease in AngI
concentrations when Angll was infused in subjects who had been treated with the
ACE-inhibitor enalapril*\ This decrement in AngI during Angll infusion can be
fully explained by the fall in renin.
The drop in AngI levels during AngI infusion, however, is more surprising. As a
matter of fact, we had expected a rise in plasma AngI concentrations, especially
since we infused human AngI. Indeed, Vos and coworkers found a substantial
increase in AngI levels during AngI infusion, but in their study not only the infused
amounts of AngI were much higher, also the ACE-inhibitor enalapril had been
administered for several days". Thus, in the latter study accumulation of AngI
could be expected. The same is true for the study of Admiraal and associates-". In
our view, only an extremely rapid conversion of AngI into Angll with simultaneous
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suppression of renin release by Angll and. hence, reduced production of
endogenous AngI could explain the fall in AngI levels which we observed in our
study. Extra-pulmonary degradation of AngI'" together with a high metabolic
clearance rate of AngI*-* could certainly be responsible for the dramatic fall in
AngI levels.
Heart rate did not change and neither did plasma catecholamine concentrations.
From earlier studies we learned that Angll concentrations had to increase thirteen-
fold in order to affect heart rate"'. The infused amounts in our experiments,
therefore could have been too low, to induce a change in sympathetic activity.
Taken together, our data suggest that the effects of AngI on blood pressure and
aldosterone release may be brought about by Angll that is, at least partly, formed
from the AngI at tissue sites. Consequently, the effects of exogenous AngI on
blood pressure and aldosterone are comparable to those of equimolar doses of
exogenous Angll. However, due to a low capacity of the kidney to convert AngI,
the renal effects of AngI are less prominent than those of Angll. It is likely thai the
effects of AngI on the kidney require the formation of Angll at extrarcnal tissue
sites.
While most effects of both angiotensins subside soon after their administration is
discontinued, suppression of renin release through the short feedback loop is long-
lasting. The latter is perhaps due to accumulation of Angll, which has been taken
up from the circulation, in renal tissue. Although our hypotheses need to be tested
in a more formal way, the data from the present study are at least consistent with
the view that peripheral tissues are capable of regulating their own local production
of Angll or uptake of this peptide from the circulation.
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Chapter 6
Possible discrimination
between the effects of
plasmatic versus tissue
angiotensin II in man
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Abstract
Objective
The purpose of this study was to evaluate whether it is possible to discriminate
between the effects of tissue and plasma angiotensin II (Angll) in man. To this end
an ACE-inhibitor was infused while plasma levels of Angll were maintained by
exogenous Angll.
Methods
Nine healthy male volunteers on a sodium-restricted diet were studied on five
separate occasions, during which in random order simultaneous infusions of
cnalaprilate (E) with either placebo (P) or Angll in doses of 0.3, 0.5, 1 or 3
ng/kg.min were given. Mean arterial pressure (MAP), heart rate, forearm blood
flow (FBF), effective renal plasma flow (ERPF), glomerular filtration rate (GFR),
renin, Angll and aldosterone (Aldo) were assessed at baseline, after 30 minutes of
the combined infusion and again 30 minutes after discontinuation of the Angll/P
infusion.
Results
Plasma Angll levels were maintained at baseline levels only during the infusion of
E with 0.5 ng/kg.min of Angll. With this combination MAP and Aldo did not
change either. However, as compared to baseline ERPF significantly fell, while
renal vascular resistance rose with the same combination (p<0.05 and p < 0.005
respectively). Renin was significantly, but not entirely suppressed by the infusion
of E with 0.5 ng/kg.min of Angll. With the other doses of Angll more pronounced
changes were noted. Both FBF and GFR remained unaltered during all
experiments. Thirty minutes after cessation of the Angll infusions, plasma levels of
Angll were hack to baseline in all experiments. However, differences remained for
ERPF, RVR and renin after the various infusions.
Conclusions
Maintenance of plasma Angll during E infusion elicits renal vasoconstriction and
incompletely suppresses renin. while leaving blood pressure and Aldo levels
unchanged. After cessation of the Angll infusion, renal vasoconstriction persists
and the more so when higher doses of Angll had been used. These effects could be
related to renal uptake of Angll from the circulation.
Introduction
• * • *
Over the last decade evidence has accumulated that, besides being a circulating
system, the renin-angiotensin system (RAS) is also present in many tissues".
Campbell even suggested that the circulating RAS merely delivers renin and
angiotensinogen to the tissues, where angiotensin I (AngI) and angiotensin II
(AngH) are generated locally*. Although data from both animals and humans
suggest that AngI and Angll may. indeed, be formed within tissues''', several
organs are also capable of extracting angiotensins directly from the plasma'"". It is
noteworthy, though, that the extraction of plasma Angll by the kidney, an organ
with an exquisite sensitivity for the action of Angll, is much higher as compared to
that by other tissues, such as the heart or the hindlimb'v These observations point
to a more active role of certain tissues in the regulation of angiotensin mediated
effects. Whatever the processes involved (uptake or local pnxluction of Angll), it is
unlikely that plasma concentrations of Angll sufficiently reflect the concentrations
of this peptidc hormone at the tissue level. Similarly, the physiological effects of
Angll may not entirely relate to its plasma concentrations.
Although there is ample evidence from experimental studies that the regulation
of tissue RAS is different and independent from the regulation of plasma RAS'"*,
until now it has been difficult to study tissue RAS in humans. Despite several
attempts to dissociate the effects of Angll from its plasma levels, in none of these
studies plasma Angll remained unaltered""'. This prompted us to set up a series of
experiments, in which we attempted to block angiotensin converting enzyme (ACE)
without lowering plasma Angll. To this end, we concurrently infused the ACE-
inhibitor enalaprilate with varying doses of Angll. In doing so, we aimed at finding
a dose of Angll that would leave plasma Angll unaltered during the administration
of the ACE-inhibitor.
Following 30 minutes of combined infusion, the administration of Angll was
suddenly stopped to allow plasma Angll to fall again. With the ACE-inhibitor
infusion still continuing, changes in hemodynamic and neurohumoral variables that
would occur upon the cessation of angiotensin infusion would now most likely be
due to the fall in plasma angiotensin II.
As it has been suggested that the circulating RAS is more important for acute
cardiovascular homeostasis, whereas tissue RAS is essential for long-term
regulation of the circulation", discrimination between the effects of circulating
RAS and tissue RAS may be most prominent during acute intervention or
manipulation of the RAS. In other words, if the effects of acute manipulation of the
RAS are mediated primarily by circulating RAS, than the observed effects should
show a tight relationship with (changes in) plasma Angll. If they are not. than
other factors, such as tissue Angll, may also play a role.
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Subjects and methods ijsft'i i inl
Nine healthy normotensive male volunteers with a mean age of 24 + 1
(mean±SEM) years and a body surface area of 1.93±0.05 m* were included in
this study. The protocol was approved by the Hospital Ethics Committee and
written informed consent was obtained from all participants. Each subject had a
medical history taken and underwent a physical examination. Routine laboratory
tests were carried out before the start of the study.
P r o t o c o l • . . ! • . . • . . - - . . .
During twelve days subjects were put on a moderate sodium restricted diet of SS
mmol/day; potassium intake was 80 mmol/day. Compliance with the diet was
checked by measuring sodium output in 24-hour urine collections obtained during
the last 6 days of the study period. Completeness of urine collections was estimated
from the concurrent creatinine excretion. Subjects refrained from smoking and
alcohol: caffeine and caffeine-like substances were also forbidden on the study
days. All volunteers were studied after an overnight fast in the morning of each of
the last five days of the dietary period. Five different experiments were conducted
according to a randomized single-blind placebo-controlled study design, where
except for the dose of Angll, experimental conditions were similar on the five
days.
All studies started at 8.00 a m and subjects remained supine during the entire
session. In both arms an antecubital vein was cannulated with a 20 G cannula: the
one in the right arm was connected to a 3-way tap for the infusion of
Angll/placebo, enalaprilate and P-aminohippurate/inulin, whereas the one in the
left arm was used for blood sampling. Subjects consumed 200 ml of water every
hour, to ensure diuresis, until the last blood samples had been drawn. After a two-
hour equilibration period, necessary to reach steady state plasma concentrations of
PAH and inulin, a bolus injection of 4 ml ( = 4 mg) of enalaprilate (MSD,
Haarlem. The Netherlands) was given followed by a continuous infusion of 0.02
mg/min. In random order on the different study days a 30 minute infusion of either
placebo (0.9% saline) or [He'] Angll (Clinalfa AG. Laufelfingen, Switzerland) in
doses of 0.3, 0.5, 1 or 3 ng/kg.min was started concurrently with the enalaprilate.
After 30 minutes of combined infusion the placebo/Angll infusion was stopped,
whereas the enalaprilate infusion was continued for another 30 minutes.
The Angll infusion rates were chosen on the basis of data in the literature on
attained plasma Angll levels during Angll infusions and from earlier experiments
in our laboratory. At least one of our infusion regimens was expected to maintain
plasma Angll levels at baseline level. Study variables were assessed and blood was
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drawn at baseline, after 30 minutes of combined infusion (t = 30) and at the end of
each experiment (t=60). Blood samples were drawn for measurement of PAH,
inulin, hematocrit and plasma levels of Angll, active plasma renin concentration
(APRC), aldosterone (Aldo) and angiotensin converting enzyme (ACE). Moreover,
mean arterial pressure (MAP), heart rate (HR) and forearm blood flow (FBF) were
assessed.
Methods
MAP and HR were measured by a semi-automatic oscillometric device (Dinamap
Vital Signs Monitor 1846, Critikon, Tampa, FL, USA). Renal hemodynamics, i.e
effective renal plasma flow (ERPF) and glomerular filtration rate (GFR) were
measured as the clearance of PAH (PAH: aminohippurate sodium; MSD, West
Point, PA, USA) and inulin (Inutest, Laevosan Gesellschaft, Linz, Austria)
respectively, using the continuous infusion method". Effective renal blood flow
(ERBF) was calculated using the following formula: ERPF/(1-hematocrit).
Filtration fraction (FF) was calculated using the equation: GFR/ERPF. Renal
vascular resistance (RVR) was calculated according to the formula:
(MAP/ERBF)*80000.
The Dinamap cuff was replaced by a pneumatic cuff for five minutes during
measurements of FBF. FBF was estimated by ECG-triggered venous occlusion
plethysmography". A pneumatic cuff connected to a rapid cuff inflator was placed
around the left arm. The cuff was inflated to 50 mm Hg during three heart beats to
impede venous back flow and was deflated again during two heart beats. Mid-
forearm expansion was measured continuously over a 5 minute period using a
mercury-in-silastic strain gauge stretched to 2% past its resting length and
connected to a plethysmographic system (Periflow, Janssen Scientific Instruments,
Belgium) and a computerized data acquisition system. Before each recording
another cuff was placed around the left wrist and inflated to 200 mm Hg to exclude
the hand circulation. Forearm vascular resistance (FVR) was calculated as:
MAP/FBF.
Active plasma renin concentration (APRC) was assessed by the IRMA-method
(Nichols Institute Diagnostics, Wychen, The Netherlands) with an intra-assay
coefficient of variation (CV) of 2.9% and an inter-assay CV of 7.6%**. Angll was
determined by radio-immunoassay (RIA) following Ph Phenyl column extraction
(Amersham Int. Amersham, UK; intra-assay CV 4.6% and inter-assay CV 7.7%)*'.
Aldosterone was assayed by means of a solid-phase protein binding RIA (Dia-
gnostic Products Corporation, LA, USA; intra-and inter assay CV 4.3% and 6.7%,
respectively)". PAH (intra-assay CV 4.2%, inter-assay CV 7.3%), inulin (intra-
assay CV 4.5%, inter-assay CV 8.1%) and ACE (intra-assay CV 3.9%, inter-assay
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CV 7.1%) levels were measured spectrophotometrically""-'.
For each substance, all samples from the same individual were assayed in a
single run.
Data analysis
To avoid the statistical problems which are inherent to the analysis of serial
measurements", we applied summary statistics to assess differences between the
infusion regimens. The two periods (0 to 30 minutes for combined infusions and 30
to 60 minutes for enalaprilate only) were considered separately. In order to
determine which infusion rate would leave plasma Angll unaltered, we first
analyzed mean changes in plasma Angll with their confidence intervals (CI) at the
end of the combined infusion (1 = 30). Subsequently, changes in all other variables
were tested at t = 30 by one-way analysis of variance or by the Kruskal-Wallis test
depending on the homogeneity of variance or normality of the data.
Prior to statistical testing logarithmic or square root transformation of the data
was performed, when appropriate. When the F-ratio was significant, contrasts were
used to compare the different infusion regimens. One contrast was defined a priori,
namely between the infusion regimen during which plasma Angll remained
unaltered and the control experiment where only the ACE-inhibitor was given. If
this yielded a significant effect, the next step was to determine whether changes
induced by the combined infusion differed significantly from zero. The latter was
done to answer the main study question.
All other data are presented in the graphical analyses. Data points at t = 60 were
analyzed in the same way. Results are expressed as means ± SEM. A p-value of
less than 0.0S was considered significant.
Results
After six days of sodium restriction all subjects were in sodium balance (38±7
mmol/24 hour), while potassium excretion amounted 58±7 mmol/24 hour.
Baseline measurements of the study population are given in table 1. Baseline data
were comparable on all five study days. ACE-activity in plasma was adequately
inhibited (measured ACE-activity below 2U/1) both at t = 30 and t=60 in all
experiments.
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Table 1. Baseline data on the five experimental days. ;j * «
Ang II (pmol/l)
APRC (mU/1)
Aldo (pmol/l)
MAP (mm Hg)
HR (bpm)
FBF (ml/lOOml/min)
ERPF(ml/min. 1,73m*)
GFR (ml/min. 1.73m*)
E+placebo
15.0±2.5
53±10
345 ±53
83±3
62 ±3
1.9±0.2
468 ±35
118±7
E+0.3 ng AH
14.1 ±2.2
57 ±9
424 ±74
84 ±3
59±3
2.2±0.3
449 ±30
114±6
E+0.5 ng All
12.7±2.2
61 ±8
280 ±53
86±2
65 ±5
2.3±0.2
591 ±49
126±5
E+1 ng All
16.6±2.2
41 ±6
522 ±103
S 82 ±4
I 57±3
2.1 ±0.5 §
492 ±38 ''
119±6
E+3 ng AH
14.5±2.3
39±8
469±117
88 ±3
55±2
2.7±0.7
495 ±38
123±5
E=enalaprilate; ANGII=angiotensin II; APRC=active plasma renin concentration; :
Aldo=aldosterone MAP=mean arterial pressure; HR = heart rate; FBF = foreann blood flow;
ERPF = effective renal plasma tlow; GFR=glomerular filtration rate
Plasma Angll concentrations
Changes in plasma Angll at thirty and sixty minutes are shown in figure 1. During
the control experiment (enalaprilate plus placebo) plasma Angll levels fell by
7.3± 1.4 pmol/l (CI: -10.3 to -4.4 pmol/1; p<0.05). Also, when the peptide was
infused at a rate of 0.3 ng/kg.min, plasma Angll fell significantly. After 30
minutes of the combined infusion the concentration of Angll had fallen by 5.2±1.9
pmol/l (CI:-9.5 to -0.9 pmol/1; p<0.05). With the two highest infusion rates (i.e.
1 and 3 ng/kg.min) plasma Angll increased by 9.9±3.7 pmol/l (CI: 1.3 to 18) and
51 ±14 pmol/l (CI: 18 to 84) respectively (both p<0.05). Only when 0.5
ng/kg.min of Angll was infused, plasma Angll did not differ significantly from
baseline after thirty minutes (change 0.2 ±1.0 pmol/1; CI: -2.3 to +2.7; ns).
At the end of the experiments (t = 60) plasma Angll had fallen below baseline
levels when 0, 0.3 or 0.5 ng/kg.min had been infused in the first half hour, while
they were back again at baseline with the two highest infusion rates (figure 1). By
analysis of variance, however, differences between the various experiments were
not significant.
2> 60-
-20
*p<0.0001
—•— placebo
—*•- 0.3 ng
- « - 0.5 ng
—•—1 ng
-»-3ng
n.s
30
Time (min)
60
Figure I. Absolute changes in plasma Angll concentrations during the various experiments.
•p<(HXXll as compared between the different Angll infusion regimens combined
with ACI- inhibition
74
Blood pressure and heart rate
Basal values of MAP and HR, defined as the mean of the last six measurements
during the two-hour equilibration period, were comparable on the different study
days (table 1). The absolute changes in MAP as recorded during the various
experiments are depicted in figure 2. At t = 30 a significant overall difference
existed among the five experiments (p< 0.002) and pairwise analysis revealed that
the fall in MAP was significantly greater during the control experiment than in the
experiment with the 0.5 ng/kg.min infusion (p<0.02). In the latter study the blood
pressure response did not differ significantly, from zero.
At the end of the experiments at t=60, i.e. 30 minutes after discontinuation of
the AngH infusion, MAP had fallen in a way that paralleled the fall in pressure
during ACE-inhibition alone. At that time the overall analysis indicated that there
were no differences anymore between the five infusion protocols (figure 2).
No significant changes in HR were observed during any of the experiments.
o> £
5-
0-
-5- «iK! 0-
*-- '"
*p<0.002
^ \ ^ ^ " " " • • - -
^ . n.s
—•- placebo
• -*-- 0.3 ng
- « - 0.5 ng
—•— 1 ng
-«—3ng
30
Time (min)
60
Figure 2. Absolute changes in mean arterial pressure (MAP) during (he various experiments
*p<0.02 as compared between the different Angll infusion regimens combined
with ACE inhibition
Regional hemodynamics
Although baseline values of ERPF were comparable on the various study days,
there was an overall difference in ERPF at t=30 (p<0.002). Compared to a rise in
ERPF at t=30 during the control experiment, a fall in ERPF was seen during the
0.5 ng/kg.min experiment (figure 3a). The difference between these two responses
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was highly significant (p<0.002). Moreover, the fall in ERPF that occurred during
the 0.5 ng experiment differed significantly from zero (p<0.05).
V At t=60 the overall difference in ERPF remained statistically significant
(p<0.001). Although ERPF had risen from t = 30 onwards during both the control
experiment and the experiment where 0.5 ng/kg.min of AngH had been infused
previously, there was still a significant difference in ERPF between the two studies
(p<0.05). However, as shown in figure 3a ERPF in the latter study did not differ
anymore from baseline at that time.
•.-•ncj »}i I'.
Ti-i «p<0.001
*p<0.002
j i ^ i"i
0 30
Time (rrtin)
60
placebo
0 3ng
0.5 ng
1 ng
3ng
2000-
(X 1000-
li
I -1000^
u
-2000-
-3000'
*p<O0001
#p<0.001
Fkjurt 3a and 3b.
placebo
0.3 ng
0.5 ng
1 ng
3 ng
30
Time (min)
60
Absolute changes in effeclive renal plasma flow (ERPF) and
renal vascular resistance (RVR) during the various experiments.
Upper panel (a). *p<0.02 as compared between the different
An(II infusion regimens combined with ACE inhibmoo,
#p<0.001 as compared between the different infusion regimens
after cessation of the Angll. Lower panel (b) idem
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Changes in RVR more or less were the opposite from those in ERPF (figure 3b).
A significant overall difference between the various infusion regimens was found at
t=30 (p<0.0001), with again a difference between the control and the 0.5
ng/kg.min experiment (p<0.005). Indeed, the fall in RVR during the control
experiment was completely prevented and even reversed by the infusion of 0.5
ng/kg.min of Angll. At t = 60 there was still a significant overall difference in RVR
between the five experiments (p<0.001) as well as a difference between the
control and the 0.5 ng/kg.min experiment (p<0.05). GFR remained virtually
unchanged during all experiments and although FF tended to change in parallel
with RVR, such trends never reached statistical significance.
Dau for forearm blood flow were calculated using all measurements during the
last minute of the 5-minute measurement interval. Baseline data were not different
on the study days (table 1) and none of the infusion regimens induced any changes
in FBF or FVR.
200-1
#p<0.005
o
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150-
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•p<0.0001
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Time (min)
•0
- • — placebo
—*•• 0.3 ng
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Hormonal respoases
There was a marked overall difference between APRC responses during the
different infusion regimeas (p< 0.0001; figure 4). Pairwise analysis revealed that
compared to control, APRC was significantly inhibited by the infusion of 0.5
ng/kg.min of AngN at t = 30 (p<0.01). The rise in APRC, however, was not
completely prevented by this dose as the rise in APRC was still different from zero
(p<0.05). At the end of the experiments (t=60) an overall difference between the
five studies remained (p<0.005) but at that time no difference emerged anymore
between the control and the 0.5 ng data.
Changes in Aldo at t = 30 were also different between the five infusion regimens
(p<0.0001). The decline in Aldo. which was seen during the control experiment,
was completely prevented by the 0.5 ng/kg.min infusion of AngH (p<0.02; data
not shown). Both at t = 30 and at t=60 changes in aldosterone were not different
from zero with this infusion rate. M • .
(Graphical analysis of the data
When one closely examines the data as they are presented in figures 2 through 4, a
striking pattern emerges. With respect to the hemodynamic changes (MAP, ERPF,
RVR) at t = 30, there seems to be a clustering of data points for the control
experiment and the experiment during which 0.3 ng/kg.min of AngH was given on
the one hand and the three other infusion regimens on the other, with a clear
separation between these two clusters. At t = 60 this clustering and separation
remained for ERPF (and RVR) but not for MAP. Interestingly, such a pattern was
not so evident for the hormonal changes. It even seems that the lowest dose of
Angll. which hardly affected the hemodynamic alterations, had already a profound
effect on renin release.
Finally, it should be emphasized that while plasma AngH levels were back to
baseline and even below that at t = 60 (with no difference between the five studies),
clear differences remained with respect to hemodynamic and hormonal data.
In figure 5 we have plotted for all infusion experiments the average changes in
response variables at t = 30 against the concurrent changes in measured AngH
concentrations. It can easily be seen that a linear relationship exists between
changes in circulating AngH and the effector variable only for Aldo. For MAP
such a relationship may exist when circulating AngH rises modestly but with
greater increases in AngH the response of MAP seems to level off. Interestingly,
estimated Y-intercepts are not significantly different from zero for MAP and Aldo,
while they are for ERPF, RVR and APRC.
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Discussion
The present study was designed to evaluate whether it would be possible in man to
discriminate between the effects mediated by plasma AngH and those that are
dependent on tissue Angll. Unfortunately, there are no pharmacological tools
available with which one can differentially modulate the plasma and tissue RAS.
AT I-receptor antagonists block the action of AngH on target organs but do not
indicate whether it is plasma or tissue Angll that they interfere with. ACE-
inhibitors, on the other hand, lower plasma Angll but probably also suppress
formation of this peptide at the tissue level. One could, of course, compare the
effects of different ACE-inhibitors with varying degrees of lipophilicity but there
would still remain uncertainty with respect to actual tissue penetration of these
drugs. Therefore, we decided to block ACE-activity while at the same time
preventing plasma Angll from falling by a concurrent infusion of Angll. As simple
as this approach may seem, as difficult it is to execute. Ideally, one would like to
clamp the Angll concentration in plasma by continuously adjusting the infusion rate
to the prevailing plasma Angll concentration but with present-day methodology
such an approach is not yet possible.
In our study we have used various infusion rates of Angll to determine which
dosis would leave plasma Angll unaltered. The different infusions were given in
random order and on separate days to minimize carry-over effects. Moreover, we
infused |Ile^| Angll which is an exact replicate of endogenous Angll.
Plasma AnjjII concentrations
As shown in figure I enalaprilate alone acutely reduced circulating Angll by almost
50%. AngH infused at a rate of 0.5 ng/kg.min together with the ACE-inhibitor was
able to prevent this fall. While a lower infusion rate had no effect on the fall in
plasma Angll, higher infusion rates caused significant increments in plasma AngH
levels. Although other investigators have also studied a combination of ACE-
inhibition and superimposed Angll infusion, in these studies the Angll was usually
given bejore plasma Angll could have been reduced by the ACE-inhibitor and in
none of these studies plasma Angll was maintained at baseline levels" **"".
Whatever infusion rate was maintained during the first half hour, plasma AngH
had returned to baseline or even below that in all experiments 30 minutes after
stopping the Angll infusion. Thus, at t = 60 there were no differences between the
various experiments with respect to plasma Angll. Therefore, if plasma Angll
would be the most important determinant of angiotensin's actions, the response
variables that we measured should also be comparable at that time. Our data,
however, indicate otherwise.
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Blood pressure and heart rate ' •"•"• ' ' • • '- ....*..sk.
Data from the literature dealing with the effects of combined administration of
Angll and an ACE-inhibitor on blood pressure are difficult to interpret since we
are either not informed about attained plasma levels of Angll". or plasma Angll
was not maintained at baseline levels-*-' or a non-natural analogue of Angll was
used'". The design of our study, on the other hand, allows a more direct
conclusion. The data from the present experiments show that blood pressure, for
one, closely follows acute changes in plasma Angll. The fall in pressure induced
by the ACE-inhibitor alone was completely prevented when plasma Angll was
maintained at baseline levels. Moreover, at the end of the experiments there were
not only no differences in plasma Angll, but also no differences in pressure.
Finally, graphical analysis of the data (figure 5) suggests a close relationship
between changes in plasma Angll and blood pressure with perhaps tachyphylaxis
occurring when circulating angiotensin increases substantially. Thus, acute
interference with the renin-angiotensin system is associated with changes in bloixl
pressure that seem to be entirely dependent on plasma Angll, there being no
evidence for a role of tissue Angll. Of course, our data do not exclude the
possibility that with time tissue factors such as reduced local formation of Angll or
accumulation of vasodilating substances contribute to the hypotensive response to
ACE-inhibition.
Heart rate did not seem to be affected by changes in plasma Angll. However,
data from the literature show that a thirteen fold increase in plasma Angll may be
required before changes in heart rate can be recorded*".
Regional hemodynamics
With respect to the effects of Angll on the peripheral circulation our data are less
easy to interpret. We studied two regional circulations as examples of a visceral
(kidney) and a non-visceral (forearm) vascular bed. In line with many other
observations'" we found that acute ACE-inhibition alone enhanced renal blood flow
and reduced renal vascular resistance, leaving glomerular filtration rate virtually
unchanged. Surprisingly, though, only a small amount of Angll was already able to
attenuate this response. When circulating Angll was kept constant during infusion
of 0.5 ng/kg.min of Angll, ERPF was even reduced and RVR increased. Thus, in
the face of acute ACE-inhibition the same plasma level of Angll is associated with
a strikingly enhanced renal vasoconstriction. How can we explain this sudden
increase in the sensitivity of the renal vasculature which apparently is independent
from plasma Angll? One possibility would be rapid upregulation of Angll receptors
secondary to ACE-inhibition but since circulating angiotensin II remained
unaltered, one would have to assume that this effect was related to extravascular
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Chapter 7
The role of sodium intake on
the effects of plasma and
tissue angiotensin II in man
MME Krekels, AJHM Houben, NC Schaper,
SA Rodriguez, PMH Schiffers, PW de Leeuw
(submitted for publication)
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Objective ' - •''
The present study sought to determine the role of sodium intake on the effects of
plasma and tissue Angll in more detail. To this end, we measured both during a
low and during a high sodium diet the effects of ACE-inhibition alone (with falling
plasma levels of Angll) and the effects of ACE-inhibition with concurrent Angll
infusion (during which plasma Angll levels remained unaltered).
Methods
Seven healthy male volunteers were studied both on a low (55 mmol/day) and a
high (200 mmol/day) sodium diet. During each diet three experiments were
performed, during which in random order simultaneous infusions of enalaprilate
(E) with either placebo (P) or Angll in doses of 0.3 or 0.5 ng/kg.min were given.
The AngM/P infusion was given during the first thirty minutes, concurrently with
the E infusion. After 30 minutes of combined infusion, the AngII/P infusion was
stopped, whereas the H infusion was continued for another hour. Mean arterial
pressure (MAP), heart rate, effective renal plasma flow (ERPF). glomerular filtra-
tion rate (GFR), renin (APRC), Angll, aldosterone (Aldo) and catecholamines were
assessed at baseline, after 30 minutes of combined infusion and again 30 and 60
minutes after discontinuation of the AngII/P infusion.
Results
On both diets levels of AngH remained unaltered during the combined infusion of
E and 0.5 ng/kg.min. Data from the enalaprilate and the 0.5 ng experiment,
therefore, were used for analysis. When only E was infused, the fall in Angll and
MAP and the rise in ERPF and APRC were significantly more pronounced during
the low salt diet. When the E was combined with Angll, levels of Angll remained
unchanged. Despite this, ERPF fell significantly, whereas APRC still rose. Only
MAP and aldosterone, like plasma Angll levels, did not change. As opposed to E
alone, no effect of sodium intake was observed during the combined infusion. Also
after discontinuation of the Angll infusion, when experimental conditions were
similar to the infusion with E alone, the responses on the low salt diet were
comparable to those on the high salt diet.
Conclusions
In the face of ACE-inhibition without the usual fall in plasma Angll. we found
proof for renal vasoconstriction on both diets. In addition, when Angll was given
before hand, the effects of sodium intake on ACE-inhibition were absent. This
seems indirect evidence for renal uptake and accumulation of Angll in the kidney.
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Over the last decade evidence has accumulated in favor of a more active role of
tissues in the regulation of angiotensin-mediated effects. For example, several
organs seem capable of extracting angiotensins directly from plasma'*. In this
respect, the extraction of plasma angiotensin II (Angll) by the kidney has proved to
be greater than that by other tissues, such as the heart or the hindlimh*. There is
not only evidence for uptake of angiotensins from the circulation, but also for
production of these peptides in various tissues. Indeed, many data from the
literature show that there is considerable production of angiotensins in heart,
kidney, skin and skeletal muscle tissue* *'.
As will be described elsewhere, we found indirect evidence for renal uptake of
Angll in man. In that study, we simultaneously infused an ACE-inhibitor,
enalaprilate. with Angll in such amounts that plasma Angll remained unaltered.
We observed that when plasma Angll concentrations were maintained at baseline
levels, systemic ACE-inhibition was associated with a striking renal
vasoconstriction. Moreover, despite the fact that after discontinuation of the Angll
infusion, plasma concentrations of Angll rapidly fell, renal vasoconstriction
persisted. These renal effects were even more prominent when higher doses of
Angll had been infused. On the basis of these data, we hypothesized that Angll had
been taken up by the kidney from the circulation. However, since our subjects
were in balance on a low salt diet, we could not exclude the possibility that sodium
restriction had rendered the kidney more susceptible to Angll. The latter would be
in keeping with the data of Navis and coworkers, who showed that in sodium-
restricted humans the dosages of Angll required to prevent the enalaprilate-induced
fall in blood pressure, caused a profound fall in renal blood flow*.
This prompted us to study the role of sodium intake on the effects of plasma and
tissue Angll in more detail. To this end, we measured both during a low and
during a high sodium diet the effects of ACE-inhibition alone (with falling plasma
levels of Angll) and the effects of ACE-inhibition with concurrent Angll infusion
(during which Angll levels remained unaltered). We hoped that the latter infusion
regimen would enable us to discriminate between plasma and tissue effects of
ACE-inhibition. The experiments with ACE-inhibition alone served as a control
experiments.
Subjects and methods
Seven healthy male normotensive volunteers with a mean age of 24 ±2 years and a
body surface area of 1.95 ±0.05 m* were included in this study. The protocol was
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approved by the Hospital Ethics Committee and written informed consent was
obtained from all participants. Each subject had a medical history taken and
underwent a physical examination. Routine laboratory tests were carried out before
the start of the study. , , „,.. ...,.,, , , ,.,, .
Protocol
Subjects were put, in random order, on a moderate sodium restricted diet of SS
mmoles/day and a sodium repleted diet of 200 mmoles/day for ten days each.
Potassium intake on both diets was fixed at 80 mmoles/day. Diets were calculated
for each volunteer by the hospital dietitian. Compliance with the diet was checked
by measuring sodium output in 24-hour urine collections obtained during the last 4
days of each dietary period. Completeness of urine collections was estimated from
the concurrent creatinine excretion. Subjects refrained from smoking and alcohol;
caffeine and caffeine-like substances were also forbidden on the study days. All
volunteers were studied after an overnight fast in the morning of the last three days
of the dietary period.
On these days three different experiments were conducted according to a
randomi/cd double-blind study design, where except for the infusion regimen
experimental conditions were similar. Studies started at 8.00 a.m and subjects
remained supine during the entire session. In both arms an antecubital vein was
cannulated with a 20 G cannula: the one in the right arm was connected to a 3-way
tap for the infusion of PAH/inulin, enalaprilate and Angll or placebo, whereas the
one in the left arm was used for blood sampling. All subjects consumed 200 ml of
water every hour, to ensure diuresis, until the last blood samples had been drawn.
After a two hour equilibration-period, necessary to reach steady state plasma
concentrations of PAH and inulin, a bolus injection of 4 ml (=4 mg) of enala-
prilate (MSD, Haarlem, The Netherlands) was given followed by a continuous
infusion of 0.01 mg/min during 90 minutes. In random order on the different study
days and different diets a 30 minute infusion of either placebo (0.9% saline) or
[Ile'l Angll (Clinalfa AG, Laufelfingen, Switzerland) in a dose of 0.3 or 0.5
ng/kg.min was started concurrently with the enalaprilate. After 30 minutes of
combined infusion, the placebo/Angll infusion was stopped, whereas the
enalaprilate infusion was continued for another hour until the end of the experiment
(t = 90).
The Angll infusion rates were chosen on the basis of earlier experiments
performed in our laboratory, where we had found that at least one of these doses
would leave plasma Angll unaltered when infused concurrently with enalaprilate.
Study variables were assessed at baseline, after 30 minutes of combined infusion
and 30 and 60 minutes after the cessation of placebo or Angll. Blood samples were
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drawn for measurement of PAH, inulin. hematocrit. Angll. active plasma renin
concentration (APRC), aldosterone (Aldo). angiotensin converting enzyme (ACE)
and catecholamines (epinephrine, norepinephrine and dopamine). In addition, mean
arterial pressure (MAP) and heart rate (HR) were assessed.
Methods !
MAP and HR were measured by a semi-automatic oscillometric device (Dinamap
Vital Signs Monitor 1846. Critikon, Tampa. FL, USA). Renal hemodynamics, i.e.
effective renal plasma flow (ERPF) and glomerular filtration rate (GFR) were
measured as the clearance of PAH (PAH: para-aminohippurate sodium; MSD,
West Point, PA, USA) and inulin (Inutest, Laevosan Gesellschaft. Lin/, Austria),
using the continuous infusion method*. Both variables were corrected for body
surface area and expressed as ml/min.1.73 m*. Effective renal blood flow (ERBF)
was calculated using the formula: ERPF/1-hematocrit, whereas renal vascular
resistance (RVR) was calculated as: (MAP/ERBF)*80.000.
PAH (intra-assay CV 4.2%. inter-assay CV of 7.3%), inulin (intra-assay CV
4.5%, inter-assay CV 8.1%) and ACE (intra-assay CV 3.9%, inter-assay CV
7.1%) levels were measured spectrophotometrically*".
APRC was measured by the IRMA method (Nichols Institute Diagnostics, Wychen,
The Netherlands) with an intra-assay coefficient of variation (CV) of 2.9% and an
inter-assay CV of 7.6%". Angll was determined by radio-immunoassay (RIA)
following Ph Phenyl column extraction (Amersham Int., Amersham, UK; intra-
assay CV 4.6% and inter-assay CV 7.7%)". Aldo was assayed by means of a
solid-phase protein binding RIA (Diagnostic Products Corporation, LA, USA;
intra-and inter assay CV 4.3% and 6.7%, respectively)". Norepinephrine (intra-
assay CV 4.5%, inter-assay CV 8.1%), epinephrine (intra-assay CV 4 .1%, inter-
assay CV 8.6%) and dopamine (intra-assay CV 3.9%, inter-assay CV 7.1%) were
assessed by a sensitive fluorimetric method, in which catecholamines are
concentrated from plasma by liquid-liquid extraction and derivatized with a
selective fluorescent agent prior to chromatography".
For each determination, all samples from the same individual were assayed in a
single run.
Data analysis
The first step in the analysis was to determine for each subject and for both diets
during which of the two combined enalaprilate/Angll infusions (0.3 or 0.5
ng/kg.min) plasma Angll remained constant, i.e. within 5% of baseline. Only data
from those experiments where no changes in plasma Angll were observed, were
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used for the analysis of the combined infusions. Data from the experiments during
which enalaprilate only had been given (control experiment) and data from the
combined infusion studies were analyzed separately. :'.'p • * " ' ; ' ' - ' <«
To avoid the statistical problems which are inherent to the evaluation of serial
measurements, we applied summary statistics on the overall responses to assess
differences in variables between the two diets"*. Prior to statistical testing
logarithmic or square root transformation of the data was performed, when
appropriate. Differences between the two diets or between the start and the end of
the experiments were tested by either one-way analysis of variance or the Kruskal-
Wallis test depending on the homogeneity of variance or normality of the data.
Results are expressed as means .+. SEM or as medians and ranges when
appropriate. A p-value of less than 0.0S was considered significant.
Results
Twenty-four hour sodium excretion averaged 176+_25 mmol during the high salt
diet, as opposed to 3 9 ^ 6 mmol during the low salt diet (p<0.05). Daily potassium
excretion, however, was comparable on the two diets (58 + 7 and 60+8 mmol
respectively). ACE-activity in plasma was adequately inhibited after the
administration of enalaprilate at all time points in ail experiments (measured ACE-
activity below 2U/I).
On the low sodium diet plasma Angll still fell when enalaprilate was combined
with the lower dose of Angll, but remained constant when a dose of 0.5 ng/kg.min
was infused. On the other hand, plasma Angll did not change with either the 0.3 or
0.5 ng/kg.min infusion when subjects were adhering to the high sodium diet.
Therefore, for the further analysis of the combined infusion studies only data from
the 0.5 ng/kg.min experiments were used.
Plasma Angll concentrations
Baseline plasma Angll concentrations were comparable on both study days for each
dietary period but were significantly increased during the low sodium period as
compared to the high sodium period (table 1). The effect of sodium intake on the
changes in plasma Angll induced by ACE-inhibition (ACE-i) alone and by
combined infusion are depicted in figure la and b. On both diets a significant fall
in Angll was noted during the control experiment (ACE-inhibition alone), but the
percentage fall was substantially greater during the low sodium diet (p<0.002).
When ACE-i was combined with Angll for 30 minutes, plasma levels of the
peptide initially remained constant but they fell again on both diets after
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discontinuation of Angll infusion. Decrements in plasma Angll were, however,
similar for the two dietary periods as opposed to the control experiments.
Table 1. Baseline honnonal data (means ± SEM)
APRC (mll/l)
Angll (pmol/l)
AUo (pmol/l)
Epi (nmol/1)
Norepi (nmol/l)
Dopa (nmol/l)
Low
E
2S±3
9.3±3.O
2I9±8O
0.06 ±0.01
0.92±0.14
0.26±0.06
tall diet
E + Angll
31 ±6
10.4±2.0
163 ±33
0.07 ±0.01
O.87±O.I9
0.24 ±0.05
High
K
S3 ±7
I1.5±I.O
296±6I
0.15 ±0.03
0.96±0.IS
0 46±0 10
ull dkl
E + Angll
62 ±9*
I2.7±2.J«
280 ±56
O.I2±O.O4»
O.79±O.I8
0.36±0.09
E^Enalaprilaie; Angll = angH>iensin II: APRC-JCIIVC plasma remn conccniratHm; Angl« angiotcnsin I. Aldo»
aktosterone; Epi«Epinephrine; Norepi• Norepinephrme; Oopa-Dopamine. *p<0.05 difference between ihc diets
if .!
/.Ill i
Time
• Low
High
Figure la. Changes in plasma Angll concentrations (pmol/l) during ACE-inhibilion alone.
Low salt diet (closed dots), high salt diet (open dots). *p-0.002 compared
between the diets
Time
Low
High .r
#p<0.05
Ib. C'hangci in plasma Angll concentrations (pmol/1) during combined infusion. Low salt diet (closed
dnts). high u h diel (open dots). #p<0 05 compared in baseline
Mood pressure and heart rate
Basal values of MAP and HR, defined as the mean of the last six measurements
during the iwo-hour equilibration period, were comparable on the different study
days during one dietary period as well as between the two diets (table 2). While
ACE-inhibition alone had no effect on MAP during the high sodium diet, it
reduced pressure significantly during the low sodium diet (figure 2a). This
difference in response between both dietary periods was statistically significant
(p<0.02). No such effect of diet was demonstrable for the experiments where
cnalaprilate had been combined with Angll for the first 30 minutes. In fact, on
both diets blood pressure remained stable during the combined infusion and fell
equally after cessation of Angll (figure 2b).
No significant changes in HR were observed during any of the experiments.
Table 2. Baseline hemodynamk data (means ±SEM)
Low salt diet
K + Angll
High salt diel
E K + Angll
MAP (mm llg)
HR (bpm)
ERHF (ml/min. 1.73m*)
GJ-R (ml/min. 1.7.1m')
RVR (unilsl
84±3
63 ±3
5I9±48
I33±9
7963 ±707
8612
65±5
591 ±52
126 ±5
7279 ±551
83±3
61 ±3
573 ±49
118±7
7197±742
86±3
« ± 3
572 ±37
126±5
7182±392
E-l-naljpiibtc. Angll - angiotensin II: Angl^angHKemin I; MAP«mean ancrial pressure. MR = heart rale.
ERPF-effective renal plasma How; GFR - glomemlar filtration rate; FF» filtration fraction:
RVR-renal vascular resistance
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Figure 2a. Changes in mean anerial pressure (mm Hg) during ACE inhibition alone Low salt
diet (closed dots), high sail die! (open dots). *p<0.02 compared between the dieu.
#p<0 05 compared lo baseline
Figure 2b. Changes in mean arterial pressure (mm Hg) during combined infusion IJIW salt
diet (closed dots), high salt diet (open dots)
Renal hemodynamics
Baseline values of ERPF were comparable on all study days (table 2). Changes in
ERPF during the experiments on the two diets for both the control and the Angll
experiments are depicted in figure 3a and b. Whereas during sodium repletion no
changes in ERPF were observed, ERPF rose by 24±6% on the low salt diet after
90 minutes of enalaprilate infusion. The difference between these two responses
was highly significant (figure 3a;p< 0.0002). When plasma Angll was maintained
at baseline level during the first 30 minutes of ACE-inhibition, no difference in
ERPF responses were apparent for the two dietary periods. Following a small yet
statistically significant fall in ERPF of 8±2% (high salt) and 9±3% (low salt)
respectively during the combined infusions (both p<0.05), ERPF rose again to
baseline levels after discontinuation of the Angll (figure 3b).
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Changes in RVR showed similar patterns, albeit in opposite direction. While the
fall in RVR after ACE-i alone was significantly greater during the low than during
the high salt diet (20±4% vs Ojf.2%; p<0.0001), no differences were observed
for the combined experiments. RVR rose significantly during the combined
infusion (high salt: 19±7%; low salt:15±9%; p<0.05 for both), but fell again to
baseline levels after cessation of the AngH.
GFR was comparable at baseline between the two dietary periods. After ACE-
inhibition alone GFR remained virtually unchanged, but after the combined infusion
an initial fall in GFR was noted (p<0.05) that remained after the AngH infusion
had been stopped. Neither the effects of ACE-inhibition alone nor those of the
combined infusion were modified by changes in sodium intake (data not shown).
30-i
High
Low
30-i
•Low
•High
Figure Ja. Changes in effective renal plasma flow (tnl'min 1 73m') during ACE-inhibition
•lone low sail diet (closed dots), high sail diet (open dots) *p<0.0002
compared between the diets
Figure Jb . Changes in effective renal plasma flow (ml/mm 1 73m") during combined
intusion. Low salt diet (closed dots), high sail diet (open dots). #p<0.05
compared lo baseline
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Hormonal responses
APRC was significantly higher on the low salt diet as compared to the high salt
diet (p<0.001; table 1). At the end of the control experiment (i.e. after 90 minutes
of enalaprilate) APRC had risen by 338±37% during sodium depletion and by
41 ±18% during sodium repletion (figure 4a). This difference in responses on the
two diets was highly significant (p<0.0003). Changes in APRC during combined
infusion of enalaprilate and Angll were comparable. After thirty minutes of the
combined infusion, when plasma Angll was still unaltered, APRC had already
significantly increased above baseline (p<0.05), there being no difference between
the two dietary periods. After the Angll infusion had been slopped, APRC tended
to rise more on the low salt diet but the difference with the high salt diet was not
significant (figure 4b).
400n
Low
High
Time
Figure 4a. Changes in active plasma renin concentration (mU/l) during ACF.-inhibiKon
alone. Low sail diet (closed dots), high salt diel (open dou). ' p < 0 0003
compared between the diets
Baseline Aldo levels were not different between the diets (table 2). Aldo levels
fell after enalaprilate alone, but changes were not different between the diets. When
enalaprilate was given together with Angll Aldo concentrations initially increased
to fall after the discontinuation of Angll. Again, no differences in responses were
observed on the two diets (data not shown).
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Baseline norepincphrine and dopamine concentrations were comparable on the
two dietary salt intakes, but epinephrine levels were significantly higher on the low
salt diet (p<0.05; table 1). All catecholamines remained unchanged on both diets
during all experiments.
400
300-
200-
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Figure 4b.
Time
C'hanget in icuve pUuiu renm concentration (mll/l) during combined infusion.
Low u h diet (ckned dots), high vill diet (open dots) #p<0.05 compared 10
Discussion
The present study evaluated the role of sodium intake on the effects of plasma and
tissue Angll. To differentiate between these effects is rather difficult, as no
pharmacological tools are yet available with which one can modulate the plasma
and tissue RAS separately. In a previous study, we employed a method which
allowed us, albeit indirectly, to study the effects of tissue Angll and plasma Angll
separately. We blocked ACE-activity while at the same time we prevented plasma
Angll from falling by a concurrent infusion of Angll. We speculated that when
during combined infusion the effects of the ACE-inhibitor were abolished, changes
in plasma levels of Angll would be responsible for the effects of ACE-inhibition.
If, however, this was not the case, tissue levels of Angll would be more likely to
be responsible. In that particular study, we found that renal hemodynamics and
renin release were not controlled by plasma Angll, but rather by intrarenal levels
of Angll.
In the present study we sought to determine whether such effects are influenced
by sodium intake. To this end. we have infused the ACE-inhibitor either alone or
together with Angll during a low and during a high sodium diet. The different
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infusions were given in random order and on separate days to minimize carry-over
effects. Moreover, we infused |Ile'J AngU which is an exact replicate of the
endogenous peptide. v ; . . . •  -> ; ^ ,-..;, .;• -jt!
* . • • - • • • • - • . • . • • • ' ( • ! . '
Effects of ACE-inhibition alone . ....
Although on both diets plasma AngU fell to comparable levels during ACE-
inhibition. the percentage fall in Angll was much greater during the low salt diet.
Moreover, the rise in renin during ACE-inhibiiion also was more pronounced
during sodium depletion as compared to sodium repletion. In line with many other
investigators we found a distinctive difference in hormonal responses to the ACE-
inhibitor with the different states of sodium balance"'". In response to a low
sodium diet renin release from the juxla-glomerular apparatus is increased'*;
subsequently, more renin is offered to the tissues and thus more Angll is formed
within the tissues. When an ACE-inhibitor is administered while the RAS is
activated, Angll concentrations both in plasma and in tissues are likely to fall to a
greater extent than when the RAS is suppressed. It is, therefore, not surprising
that, as Angll levels declined by 56% on the low salt diet but only by 21% on the
high salt diet, the effects in the kidney and the other tissues were stronger during
the low sodium intake. As a consequence of this exaggerated fall in Angll, the rise
in renin levels, secondary to the interruption of the negative feedback suppression
by Angll, was also more pronounced. The same was demonstrated by Jackson and
associates, who suggested that the negative feedback effect of Angll on renin
release was of relatively greater magnitude during sodium depletion'".
With respect to suppression of aldosterone concentrations during ACE-inhibition,
we were not able to demonstrate a difference between the diets. Jackson el al., on
the other hand, found that besides Angll, also aldosterone showed a more profound
fall on a low salt diet'". These controversial results are difficult to explain. In the
latter study enalaprilate was given orally and the peak effect occurred 8 hours after
administration of enalaprilate. Perhaps, a sodium-dependent dissociation in
aldosterone response does occur, but later in time. Our ninety minute infusion,
therefore, could have been too short to allow the dissociation to appear.
As Angll stimulates catecholamine release from the adrenal medulla, one would
expect that converting enzyme inhibition induces a decrement in norepinephrine
levels. However, like other investigators we did not find any change in plasma
catecholamines during ACE-inhibition*"".
Except for the dissociation in hormonal responses between the diets during ACE
inhibition, we also observed different responses of both renal and systemic
hemodynamics on the two diets. That is, the fall in blood pressure and renal
vascular resistance was more pronounced when subjects adhered to a low sodium
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diet, whereas on this diet renal plasma flow was increased to a greater extent.
These results are in keeping with other data in the literature, showing that the
hemodynamic responses to ACE-inhibitors are more pronounced when subjects are
in balance on a low sodium diet'*"**. The results from our control experiments
thus confirm that the effects of ACE-inhibition with the concurrent falls in plasma
and tissue Angll, are influenced to a major extent by the state of sodium balance of
the individual. These data are neither new nor unexpected, but they stress once
more the importance of sodium inuke when one studies the renin-angiotensin
system.
Effects of ACE-inhlblllon in combination with Angll
When an infusion of 0.5 ng/kg min Angll was added to the enalaprilate infusion,
plasma levels of Angll remained unaltered on both diets. Surprisingly, with this
approach, we observed a fall in renal plasma flow. The magnitude of the renal
vasoconstrictor response, however, was similar on the two diets. We have to
assume that in the kidney the vasoconstrictor effect of Angll prevailed over the
vasodilating action of enalaprilate. This can be explained either by incomplete
inhibition of ACE in the kidney or by uptake of Angll from plasma. We are in
favor, however, of the renal uptake hypothesis, as it is very unlikely that a
vasoconstrictor response is elicited by incomplete renal ACE-inhibition. In support
of the renal uptake hypothesis. Van Kats and coworkers recently demonstrated in
the pig, (hat arterially delivered Angll can indeed be taken up by the kidney, thus
leading to higher intrarenal levels of AnglF. We feel, therefore, that our data,
albeit indirectly, suggest that such a mechanism may also be operative in human
kidneys.
In contrast with the control experiment (enalaprilate alone) sodium inuke did not
seem to have any influence on the effects of the combined infusions of enalaprilate
with Angll As the fall in Angll on the low salt diet exceeded that on the high salt
diet, it is likely that the biological sequelae of a fall in plasma Angll are more
pronounced too during low sodium intake. Why is it then that during the combined
infusion of Angll and enalaprilate the effect of sodium was absent? In the case of
blood pressure and aldosterone the situation seems clear because changes in these
variables depend entirely upon changes in plasma Angll. Since there were no
changes in plasma Angll during the combined experiments on either diet, no
differences in the responses of blood pressure or aldosterone were to be expected.
In the kidney maintenance of plasma Angll elicited a vasoconstrictor response
which was independent of the diet. A possible explanation for these findings is that,
when renal Angll production is inhibited by enalaprilate, the kidney starts uking up
Angll from plasma. Normally, however, plasma Angll would fall, so that the
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kidney would get depleted from Angll. During our combined infusions, on the
other hand, renal uptake of Angll was still possible so that this organ could satisfy
its 'hunger for Angll'. As plasma Angll was available for uptake during both
dietary periods, it follows that the vasoconstrictor response did not have to differ.
Although intrarenal levels of Angll in the kidney due to uptake, appear to be
higher than in plasma, the rise in renin during combined infusion of enalaprilate
and Angll on both diets was not completely abolished. In our view another
mechanism, at least partly, must be responsible for the rise in renin during ACE-
inhibition. In this respect there could be a role for bradykinin** - \
A closer look at the data after the discontinuation of Angll reveals an interesting
feature. Because the effects of Angll are known to last only for one circulation
time, one would expect the effects of ACE-inhibition one hour after cessation of
the Angll to mimic those during the control experiment (ACE-inhibition alone).
However, when Angll was infused beforehand, the effects of ACE inhibition were
comparable on both diets. This is in contrast to the effects which were observed on
the low salt diet which exceeded those on the high salt diet, when no Angll was
infused in the previous thirty minutes. In other words, while the experimental
procedures were similar after discontinuation of the Angll, the effects of ACE-
inhibition were not. Because the half life of Angll is known to last less than a
minute it is very unlikely that this phenomenon can be attributed to infused Angll.
In our opinion, these data strongly suggest uptake and accumulation of Angll in the
kidney and possibly also in other tissues. We hypothesize that the uptake of Angll
by various tissues was facilitated because the plasma compartment was relatively
saturated with Angll, while the tissues were depleted in Angll by our enalaprilate
infusion. By this mechanism the tissues may have been loaded with Angll during
the exogenous Angll infusion.
In spite of the fact that the evidence for uptake and accumulation is indirect, we
think that our results corroborate other data from the literature. Indeed, evidence
has been found, just recently, for entrapment of Angll in the kidney". This Angll
appeared to be relatively protected against rapid degradation and could, therefore,
exert its effects for a longer period of time. In other words, the half-life of
intrarenal Angll was much longer as compared to that of plasma Angll. Of course,
this theory can be extended to the other study variables. For instance, as a
consequence of the accumulation of Angll in the kidney, also renin is inhibited to
the same extent on both diets. This in turn leads to virtually the same renin levels
in the plasma compartment. Accordingly, the same amounts of renin are delivered
to the tissues, where Angll is generated locally". This may explain why plasma
Angll levels after cessation of the Angll were not influenced either by the sodium
status, as was the case during the control experiment.
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In summary, we found that during ACE-inhibition and Angll infusion, despite
the fact that Angll remained unaltered, the kidney reponded with vasoconstriction
as though it was exposed to higher levels of Angll. This vasoconstrictory respone
was not influenced by the individual's sodium balance. In addition, when the Angll
infusion was stopped and the experimental conditions were similar to the
experiment where only enalaprilate was infused, the effects of ACE-inhibition were
not comparable to those during the control experiment. We feel that these data
provide evidence, albeit indirectly, for uptake and accumulation of Angll in the
human kidney.
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Chapter 8
General Discussion
Introduction
Salt is an indispensable ingredient of modern society. Except for being a tasty
constituent of food, however, it also has profound effects on cardiovascular
homcostasis and under certain conditioas may even be harmful to the individual'.
In this respect, the relationship between salt intake and hypertension remains a
controversial issue. On the one hand, there is evidence from epidemiological
studies that the prevalence and severity of an elevated pressure are related to
average sodium intake when different populations are compared"'. On the other,
however, such an association is less striking within given populations*. From a
sceptic point of view, therefore, one would be inclined to conclude that the
hypertensive effect of sodium is apparent only when extreme situations are
compared and that the observed cross-cultural differences are due to 'ecological
confounding''.
Several years ago the results of the Intersalt study were published showing a
significant positive relationship between urinary sodium excretion (as an index of
salt intake) and systolic blood pressure across 52 populations'". However, these
results were largely determined by only four populations with an extremely low salt
intake When these four populations were excluded from the analysis, the
relationship between urinary sodium excretion and blood pressure was no longer
apparent. Recently, the results of Intersalt have been revisited after multivariate
correction for regression dilution bias\ The updated report shows even stronger
associations with concordant results across and within populations.
Although unadjusted data from the largest within-population study that is
available today, the Scottish Heart Health Study*, revealed an association between
sodium and blood pressure, the relationship disappeared after adjustment for
several confounding factors. In the light of the data from Intersalt and the Scottish
Heart Health Study (the most rigorous studies known) Swales concluded that
previously reported associations between salt intake and blood pressure must be
largely attributable to confounding factors*.
An interesting finding that has been put forward by the Intersalt investigators is
that the rise in hlot>d pressure with age is stronger in societies with a high salt
intake. This suggests that sodium exerts at least a permissive action on long-term
blood pressure regulating mechanisms. Perhaps, such a long-term effect of sodium
is more important than the acute or short-term modulation of blood pressure.
Despite their tlaws. the epidemiological studies provide some evidence that the
relationship between sodium intake and blood pressure is curvilinear rather than
linear. In other words, the effect of sodium on blood pressure is more apparent in
the low and medium than in the high range of sodium intake. Although the
threshold level is not known, it is estimated to be somewhere between 50 and
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100 mmol per day"". However, such a characteristic may also be dependent on
age"•'*. Furthermore, a marked heterogeneity in blood pressure responsiveness to
alterations in dietary sodium intake has been observed, which has given rise to the
concept of sodium sensitivity'". •
Sodium restriction in hypertension -
The response to sodium restriction in patients with essential hypertension is rather
unpredictable. In fact, only about 50% to 60% of" such patients show a fall in blood
pressure on a low salt diet and the relationship between changes in sodium intake
and changes in blood pressure is not evidently linear". Furthermore, elderly
patients and subjects with moderate to severe hypertension may benefit more from
sodium restriction than younger patients with milder forms of hypertension'* ' \ We
must also realize that it may take some time before the effect of sodium restriction
on blood pressure becomes fully apparent"'. Even more striking is the observation
that some individuals respond with a rise rather than a fall in pressure during salt
restriction'^. Thus, there is again a marked heterogeneity in the way blood pressure
changes when dietary salt consumption is reduced.
The results from both the epidemiological studies and the intervention trials can
be explained by assuming that people differ in their susceptibility to the blood
pressure raising effect of salt'". This phenomenon of so-called sodium sensitivity of
blood pressure has received a great deal of attention over the past fifteen years as
will be discussed below.
Sodium sensitivity of blood pressure
The concept of sodium sensitivity originates from observations made almost twenty
years ago when individual blood pressure responses to variations in salt intake were
explored. Subjects were classified as being salt-resistant or salt-sensitive depending
upon the magnitude of their blood pressure change when going from a low to a
high sodium diet'*". Subsequently, many studies have addressed the issue of
sodium sensitivity but the experimental protocols and the working definition of
sodium sensitivity in these studies have varied considerably*'*'. For instance, some
investigators employed an intravenous sodium load or diuretics to study the
sodium-dependency of blood pressure, while others have studied the effects of
dietary intervention. Moreover, some authors have defined sodium sensitivity in
terms of absolute changes in pressure while others relied more on relative changes.
Both diastolic and mean blood pressure have been taken as the target pressure and
the classification into salt-sensitive and salt-resistant individuals has been based on
the extremes of blood pressure changes during a sodium challenge by some and on
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a simple dichotomy by others. It is evident, therefore, that it is hardly possible to
compare the results from the various laboratories. There have not been many
studies in which the reproducibility of sodium sensitivity testing has been assessed,
but available information suggests that for several working definitions the
categorization of subjects is reasonably reproducible*''•*.
The key question with respect to sodium sensitivity of blood pressure is whether
this represents an all-or-nothing or a gradual phenomenon. From the discussion
above one may already infer that the latter possibility is the more likely one.
Indeed, when one plots the sodium-dependent changes in blood pressure as a
histogram, the data follow a Gaussian distribution both in normotensives and in
hyperteasives™ *\ In this thesis we present data from a large group of hypertensive
patients who were subjected to sodium restriction (Chapter 3). When their changes
in blood pressure after one week of reduced salt intake were examined, we also
found such a Gaussian distribution (figure 1). In our opinion, therefore, it is better
to speak of the degree of sodium seasitivity than of sodium sensitivity as a
categoric phenomenon with an arbitrary cut-off point. A greater degree of sodium
sensitivity then seems to occur in subjects who are older or more obese or who
have a higher basal blood pressure. In addition, several other genetic, metabolic
and neurohumoral correlates have been identified'"*". There is also a
preponderance of data linking sodium sensitivity to a renal abnormality'""',
although the nature of this abnormality is not well understood.
Most investigators tend to believe that a defect in sodium excretion leads to a
greater expansion of extracellular volume and thus higher blood pressures in salt-
sensitive individuals.
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Figure I. Frequency dnttibuiion of changes m Mood pressure during sodium restriction
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However, before discussing the evidence for this hypothesis in more detail, it is
necessary to first review the renal excretory response to a (sudden) change in
sodium intake. Since our studies deal with sodium restriction only, we will focus
on the renal adaptation to a low salt diet. .
• • • . : • . • • . • • „ • • • . - • • • i . v - v * • - • •
The renal adaptation to sodium restriction ' ' «ai
The kidney responds to alterations in body fluid volumes by rapidly adjusting
urinary sodium output, but the mechanisms that control body sodium are
incompletely understood. If there is an increase in extracellular or effective
circulating volume, sodium excretion will rise in order to restore this volume.
Conversely, sodium output will fall in case of volume depletion. When a subject
switches from a high to a low salt diet, it takes a few days before urinary sodium
excretion matches the new intake. In other words, during the first day of restriction
sodium excretion still is in excess of sodium intake, thus leading to a fall in
extracellular volume'''. It is assumed that in subsequent days sodium excretion and
extracellular volume gradually fall to their new steady state. The latter is based
upon the observations by Strauss and coworkers who also noted that, once a subject
is in balance on a very low sodium intake, even a small increase in the amount of
sodium ingested will be excreted"'. This had led to the hypothesis that there is a
critical state between surplus and deficit of body sodium that the organism tries to
maintain following changes in sodium intake. If more sodium is ingested, the
excess will be excreted while sodium will be retained when intake falls below the
critical state. The concept of Strauss and associates was further elaborated on by
Hollenberg who introduced the term 'set point for sodium homeostasis'". This set
point or basal level of body sodium as it was later called by Simpson" would be
maintained when sodium intake is very low. The idea of a set point of sodium
homeostasis was criticized by Bonventre and Leaf who argued that a shift in
sodium intake is associated with concurrent alterations in total body sodium and in
body weight". In fact, they considered the regulation of sodium in the body as a
series of steady states with contributions from many systems, only one of which
would be sodium intake. Later, Simpson has tried to unify both views by pointing
out that the set point and the steady state theory are not mutually exclusive because
the basal level of body sodium represents a very special steady state". Against the
theory of a particular set point that the organisms tries to be on all the lime is the
observation that cumulative sodium balance and extracellular volume change with
the level of sodium intake*"'. Thus, available evidence suggests that the transition
from high to low sodium intake is associated with a fall in body sodium towards a
new steady state. It is not unreasonable to hypothesize that this fall in body sodium
stops below a certain critical level as proposed by Hollenberg" and Simpson".
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Most investigators emphasize the exponential decay in sodium excretion (with a
half-time of approximately 24 hours) when a subject switches from a high to a low
salt diet*"-"'*. However, Simpson questions whether this is an adequate and valid
assumption" and the data described in Chapter 2 of the present thesis seem to
support his doubts. When we put a group of essential hypertensive patients on a
low salt diet, containing SS mmol of sodium per day, we did, indeed, find an
exponential decay in sodium excretion when the data of the whole group were
analyzed. However, we were struck by the fact that even after one week of sodium
restriction (when in (he whole group average sodium output matched intake), the
variability in sodium excretion between subjects was as great as it was before the
dietary intervention. We then proceeded by examining all individual patterns of
changes in sodium excretion separately. This analysis revealed four different
patterns by which subjects can attain their new level of sodium excretion. Of
course, we cannot exclude the possibility that there are even more patterns.
Although the recognition of the various patterns may seem a rather nap-hazard
process, all excretion data had been given to a panel of four assessors who had to
agree on the categorization of the data. The pattern, that we designated as type 1.
was indeed the typical exponential decay but this pattern was encountered in only
one-third of the patients. In 10 patients we found an oscillating pattern as if the
kidney was 'seeking' the appropriate level of sodium output. In another third of the
patients an initial fall in sodium excretion was followed by a secondary rise and in
17 patients sodium excretion remained high for several days after the change in
diet. It is not surprising, therefore, that there were marked differences in
cumulative sodium loss between patients.
Since our study was a descriptive one without aiming to find the mechanisms
behind the different sodium excretory patterns, we cannot but speculate about the
nature of the differences in renal responses. In the light of the foregoing discussion
about the regulation of body sodium one would be inclined to attribute the different
patterns to variations in the responsiveness of sodium conserving mechanisms. A
greater sodium loss, such as occurred in group 4, could then be due to either
insufficient activation of sodium-retaining hormonal systems, e.g. the renin-
angiotensin system, or to a tendency of the organism to get rid of an excess of
body sodium (with appropriate suppression of sodium-retaining mechanisms). In
group 2 and 3 a sodium-retaining and a sodium-losing state alternate. Perhaps
pattern 3 is a slow variant of pattern 2. Clearly, further studies are necessary to
explore the nature of the various patterns but at this time it is important to realize
that the kidney has many ways to adapt to changes in sodium intake. Consequently,
it cannot be predicted beforehand how cumulative sodium balance will change
following sudden restriction of dietary sodium.
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Renal function, sodium balance, and sodium sensitivity
Given the variability in sodium excretory patterns as described above, increases or
decreases in salt intake may be associated with greatly varying amounts of sodium
that are gained or lost by the body. Thus, on the premise that body sodium is an
important determinant of blood pressure, the kidney may play a decisive role in the
pathogenesis of sodium sensitivity. This view is supported, amongst others, by the
fact that both in normoteasives and in hypertensives the age-related increase in the
prevalence of salt sensitivity correlates with a concurrent decline in creatinine
clearance*". Moreover, a salt-induced rise in blood pressure is associated with a
reduced vasodilator response in the kidney". Finally, the observation that sodium-
sensitive subjects retain more sodium and gain more weight upon a high salt diet
suggests that the kidneys of these individuals are unable to excrete a sodium load
fast enough'*. Conversely, these sensitive subjects need more time to achieve
sodium balance when they are put on a salt-restricted diet. The latter data suggest
that salt-sensitive patients are characterized by a sluggish renal response to
alterations in sodium intake, rather than by a primary tendency to retain sodium.
Indeed, Wedler and coworkers have even presented evidence against the sodium-
accumulation theory'''. When they analyzed their data on the blood pressure effects
of sodium restriction, they also noted a longer half-time for the elimination of
sodium in salt-sensitive hypertensive subjects. In normotensives, on the other hand,
half-times did not differ between sodium-sensitive and sodium-resistant subjects.
They further found that the greater the sodium intake, the longer the elimination
half-time. From these and some other observations the investigators concluded that
the time to reach sodium balance may increase after salt-sensitivity has been
established rather than before that. In other words, the tendency of sodium-
sensitive hypertensives to retain more sodium may be a secondary phenomenon.
The data presented in Chapter 4 of this thesis indirectly support those of Wedler
and associates. In our hypertensive population the average fall in body sodium was
comparable for those with the greatest and those with the least fall in blood
pressure. Thus, being more sodium sensitive does not necessarily imply being less
able to conserve sodium during a phase of sodium restriction. On the basis of these
observations we have come to the conclusion that, although the development of
sodium sensitivity may be related to aging or to a decline in renal function, there is
as yet no compelling evidence that a tendency to retain an excessive amount of
sodium is a primary event in salt-sensitive hypertension. Furthermore, it is difficult
to see how a primary renal defect in sodium excretion could be operative only
during sodium loading and not during sodium restriction when there is a tendency
to lose extra sodium. The latter is precisely what occurred in group 4 of the
patients described in Chapter 2 of this thesis. Those patients had the greatest fall in
pressure (in other words: were the most sodium-seasitive) and their renal
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adaptation to the new sodium intake appeared to be very slow. Available data,
therefore, seem to support the view that the kidney of salt-sensitive people is
characterized by an inability to respond fluently enough to (acute) changes in
sodium coasumption. This abnormality could either reside in the kidney itself or
represent a failure to recruite extrarenal mechanisms that are involved in sodium
homeostasis such as the renin-angiotensin system. There is also evidence that
vascular abnormalities may be involved in sodium sensitivity*"*'. ; «;
Even though a greater degree of sodium seasitivity may be accompanied by a
defect in renal sodium excretion, changes in body sodium may be a covariate rather
than a cause of salt-sensitive hypertension. In fact, in our studies we could not
detect any relationship whatsoever between changes in blood pressure and
cumulative sodium loss (Chapter 3 and 4). These results are consistent with those
from at least two other studies"". Another interesting observation that tallies
nicely with our data comes from Koomans and coworkers". In patients with end-
stage renal disease these investigators found an enhanced sensitivity of blood
pressure to changes in sodium intake, and they even noted an inverse correlation
between creatinine clearance and the degree of sodium sensitivity. In the same
study, however, they observed only a weak relationship between salt-induced
increases in extracellular volume and concomitant rises in pressure. Remarkably,
for any increment in extracellular volume, the pressure tended to rise steeper in
patients with more advanced renal failure. Also in comparison to normal subjects, a
similar expansion of extracellular volume was associated with greater rises in
pressure in the renal failure patients*'. Thus, volume retention per se cannot be the
sole factor that is making the pressure sodium-sensitive. Although an abnormality
of sodium balance may contribute to the degree of sodium sensitivity, it does not
seem to be a prerequisite. Likewise, a rightward shift in the pressure-natriuresis
curve as suggested by Guyton*\ may be a secondary rather than a causative
phenomenon.
The renin-ungiotensin system and sodium sensitivity
Most investigators have described low levels of renin and prorenin**^ or a blunted
rise in renin with sodium restriction in salt-sensitive people'**'"". Likewise,
sodium-sensitive individuals display a blunted suppression of renin during a high-
salt diet, leading to inappropriately high renin levels. However, from a theoretical
point of view an unresponsive renin system could merely be due to only modest
changes in body sodium during the dietary intervention. With this in mind, we
measured cumulative sodium balance during one week of sodium restriction in
hospitalized patients with essential hypertension. Renin levels were assessed at the
end of this period. In this study (Chapter 3) we found, as already stated above, that
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the degree of sodium sensitivity of blood pressure could not be explained by
differences in cumulative sodium loss. In fact, when we divided the subjects in
tertiles according to the final fall in pressure, the tertile with no change in pressure
had the same fall in cumulative sodium balance as the tertile which showed the
greatest decrement in pressure. Moreover, the magnitude of the blood pressure fall
did not correlate whatsoever with the amount of sodium lost. However, renin levels
at the end of the observation period (with all subjects being in sodium balance)
were significantly higher in the tertile with no change in pressure than in the tertile
with the greatest fall in pressure. These data strongly suggested that nol sodium
loss, but the degree of renin activation is the key factor which determines to wliai
extent blood pressure responds to alterations in sodium intake.
In a second study (Chapter 4) we went a little further by examining the dynamic
behavior of renin and aldosterone after a sudden decrease in sodium intake. This
study, in a smaller group of patients, confirmed our earlier findings that there is no
relationship between cumulative sodium loss and the change in blood pressure.
Contrary to others"" we could not find a relationship either between baseline renin
levels (i.e. when patients were still on their habitual diet) and the final changes in
blood pressure. However, a weak positive relationship was observed between the
early renin response, that is the rise in renin during the first three days of sodium
restriction, and the difference between final and initial blood pressure. In other
words, a greater renin response during the first few days of sodium restriction is
qssociated with a lesser fall in pressure. Although our data confirmed that salt
sensitivity is linked to a blunted responsiveness of the renin system"""* "•****•"•",
they also demonstrated that renin levels at the new steady state (i.e. after one
week) had no relationship with the ultimate changes in blood pressure. From these
data we concluded that a relative or absolute inability of the renin system to change
with alterations in salt intake determines the degree of sodium sensitivity of blood
pressure. This unresponsiveness (or perhaps delayed responsiveness) is not coupled
to the low-renin state as a number of patients with normal renin levels appeared to
display the same phenomenon. A relatively 'fixed' renin system may, however, be
related to the non-modulator status as described by Hollenberg and coworkers" **.
According to their theory the intrarenal production of angiotensin II is
inappropriately high in relation to sodium intake, thereby shifting the pressure-
natriuresis curve to the right. As attractive as this hypothesis may seem, it does not
account for the fact that renal sodium output is sometimes impaired (as during
sodium loading) and sometimes facilitated (as during sodium restriction). On the
basis of our own data and those from the literature, we have come to an
alternative, although related, hypothesis. Assuming that the regulation of volume
control takes precedence over other regulatory systems, including those which are
engaged with blood pressure, we may explain our findings as follows. When a
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subject is confronted with a sudden decrease in sodium intake, sodium excretion by
the kidney will fall only slowly. Counterregulating sodium-conserving mechanisms
will be activated to prevent the organism from too great a volume loss. Activation
of the renin-angiotensin system probably is one of the main, if not the most
important, defense mechanisms against volume depletion. If, for some reason,
activation of renin is insufficient the organism faces the threatening of dehydration,
necessitating the recruitment of other sodium-conserving mechanisms. As blood
pressure itself is a very powerful regulator of sodium excretion, it follows that a
drop in pressure may halt ongoing sodium loss. Thus, one could consider the
sodium-related fall in pressure as a protective mechanism. In this view, sodium
sensitivity of bIcxxJ pressure is an adaptive phenomenon of volume control rather
than a primary abnormality. Exactly the opposite may then occur during sodium
loading. Further studies are necessary, however, to put this hypothesis to the test
and to explore by which mechanisms blood pressure falls under these
circumstances.
The rcnin-angiotensln tytfcm: general aspects
II the hypothesis presented above is correct, sodium sensitivity of blood pressure is
an important protective mechanism coming into play when the renin-angiotensin
system fails. But even when our view is wrong, the crucial role of the renin-
angiotensin system cannot be emphasized enough. In the second part of this thesis,
therefore, we have focused our attention on the (patho)physiology of this system.
Since we wanted to investigate some fundamental aspects of the function of
angiotensin II, the effector peptide of the system, we turned from patients to
normal volunteers in order to better understand the physiological mechanisms that
are normally involved in cardiovascular regulation.
Classic endocrinology holds the view that the renin-angiotensin system is a
circulating system with renin being produced in the kidney and acting in plasma on
circulating angiotensinogen. The decapeptide angiotensin I (AngI) which is created
by this reaction, is further degraded to the ociapeptide angiotensin II (Angll). The
latter reaction is catalyzed by angiotensin-converting enzyme (ACE) which is
abundantly present in the pulmonary capillary bed. Angll then enters the systemic
circulation to exert its effect on various target tissues such as the kidney, the
adrenal cortex, the vascular wall and the brain. Local effects are mediated by
specific receptors, mainly of the ATI type.
Over the past decade evidence has accumulated in favor of the existence of local
renin-angiotensin systems". Since most components of the renin-angiotensin system
have been found at the tissue level, it is conceivable that Angll may be produced
locally. In particular. ACE is richly present on the endothelial cells of all blood
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vessels'*. However, it is still uncertain whether Angll that is present in tissues is
formed locally or taken up by tissues from the circulation. The same applies to the
other components of the renin-angiotensin system. By means of molecular
biological techniques mRNA's for angiotensinogen, renin and ACE have been
demonstrated in many tissues involved in cardiovascular regulation", making local
synthesis of these substances a distinct possibility. Most of this information,
however, has been obtained in experimental animals and it is not certain whether
the situation is entirely similar in humans. Some investigators believe that tissue
renin, e.g. in the heart, is not locally synthesized, but rather taken up from the
circulation". It has to be stressed that tissue renin needs both renin substrate
(angiotensinogen) and ACE before it can generate angioiensin II. On the other
hand, only tissue ACE is required to allow local conversion of AngI into Angll.
Since ACE is so ubiquitously present in the vascular system, local conversion of
AngI seems almost inevitable. Accordingly, the functional role of tissue renin is
much more debated than the role of tissue ACE. If tissue ACE is functionally
active, its substrate AngI may either be synthesized locally or taken up from
plasma.
Although it is generally held that most AngI is converted in the pulmonary
vascular bed, the quantitative contribution of other vascular beds to conversion of
arterially delivered AngI should not be overlooked". Nevertheless, circulating
Angll is mainly derived from conversion of blood-borne AngI and there is little
evidence that locally converted AngI reaches the circulation in the form of Angll'*.
Recent observations demonstrate that, especially in the kidney, circulating Angll
may accumulate during Angll infusion'''. These data are compatible with tissue
uptake of Angll and suggest that tissue Angll may be derived from two sources:
local production and uptake from the circulation.
As described in this thesis we have tried, in a series of experiments, to gain
more insight into the possible role of tissue angiotensins in man. The first question
we asked ourselves was whether the hemodynamic and humoral effects of
circulating angiotensin I should be explained by conversion of AngI into Angll in
the plasma compartment or rather by tissue conversion of AngI. Subsequently, we
performed two experiments to assess, in man, whether it is possible to discriminate
between the effects of blood-borne angiotensin II and those of tissue angiotensin II.
Comparison of the effects of angiotensin I and angiotensin II
In plasma, AngI circulates in concentrations that are several times higher than those
of Angll, suggesting that conversion of AngI in plasma is a slow process. Still,
ACE is a key factor in the production of Angll. A compelling question, therefore,
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is to what extent a rise in circulating Angl is able to produce hemodynamic and
humoral effects. One may achieve a rise in plasma Angl by exposing the
individual, for instance, to mild volume depletion. This manoeuvre, however, will
also increase circulating renin which in turn stimulates the release of Angl and
Angll from extrarenal tissue sites*". We preferred, therefore, to infuse Angl and to
compare the effects of this peptide to those of equimolar doses of Angll. We
reasoned that if all infused Angl would be converted to Angll on a 1:1 molar basis,
the effects of the two angioleasins should be similar. Any discrepancy between the
results of both infusion experiments would likely be related to either insufficient
conversion of Angl (in plasma or at the tissue level) or uptake and degradation of
Angl. The results of our experiments have been described in Chapter 5 of this
thesis. They show that attained plasma levels of Angll following infusion of Angll
amount to approximately 80% of those reached when Angll had been infused. Still,
Angl and Angll had similar effects on bl<x>d pressure and on aldosterone release
suggesting that Angll concentrations in the target tissues (peripheral vasculature
and adrenal cortex) were comparable after Angl and after Angll infusion. Thus, it
is tempting to speculate that about 80% of the infused Angl had been converted in
the plasma, most probably by soluble ACE, whereas the remaining 20% was
converted at the tissue level. These proportions are remarkably similar to those
found by others in completely different experiments*"*"'''. Compared to the changes
in blood pressure and in aldosterone, the effects of Angl on the kidney were less
than those of Angll. This was not only true for the renal hemodynamic changes but
also for the extent of renin suppression. Hence, our data are compatible with those
suggesting no or only low-grade conversion of arterially delivered Angl in the
kidney'"*"*'. If this is true, it is likely that the fall in renal perfusion and the
suppression of renin occurring during Angl administration are not caused by
intrarcnally converted Angl, but rather by Angl that has been converted elsewhere
in the vascular bed and that has subsequently entered the systemic circulation again
as Angll.
Plasma versus tissue angiotciisin II
A matter that is still difficult to pursue in the intact human being is the
differentiation between the effects of plasma Angll and those of tissue Angll. As
we have argued in Chapter 6 of this thesis, classical pharmacological experiments
with either different ACE-inhibitors or drugs that bind to angiotensin receptors, are
bound to yield uninterpretable results. In the studies that we performed, and that
we have described in Chapters 6 and 7, we attempted to block the formation of
Angll by enalaprilate, while at the same time leaving plasma Angll unchanged by a
concurrent infusion of this peptide. We have, indeed, succeeded in creating such a
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situation. When subjects were studied, who were in balance on a low salt diet, it
soon became evident that there was a marked dissociation in response between the
kidney and other tissues. Compared to ACE-inhibition alone (with falling levels of
plasma Angll), ACE-inhibition with maintained plasma Angll completely abolished
the fall in blood pressure and in aldosterone. Thus, the effects of converting
enzyme inhibition on the systemic vasculature and on aldosterone release seem to
be mediated entirely by plasma Angll.
Our data further show that the kidney responds differently to interference with
Angll formation. While ACE-inhibition alone was associated with substantial
vasodilation, the opposite was found during the combined experiment. Since it is
difficult to see how renal vasoconstriction could be brought about in the face of
unaltered levels of circulating Angll, we assume that the fall in renal plasma flow
during combined administration of enalaprilate and angiotensin II is due to an
increase in intrarenal Angll levels. Theoretically, the latter could be the result of
either enhanced intrarenal production of Angll or of uptake of Angll from the
plasma. Again, it is difficult to see why the kidney would speed up the synthesis of
Angll during a state of ACE-inhibition with constant plasma levels of Angll. In our
view, therefore, renal uptake of Angll is a more likely explanation. Recent
experimental data support the potential existence of an uptake mechanism'"'". We
may now think of the kidney as an organ that becomes 'hungry' for Angll during
ACE-inhibition. In other words, when intrarenal levels of Angll fall, the kidney
may start to take up as much Angll as possible from the circulation, even when
intrarenal ACE is not entirely blocked. The extracted Angll may be stored in a
compartment of the kidney that is relatively protected against angiotensinases.
Indeed, others have pointed also to the compartmentalization of angiolensin in the
kidney*"". The prolonged presence of Angll in the kidney may thus explain the
slow return of renal perfusion and renin release after the combined
enalaprilate/angiotensin II infusions (Chapter 6).
We stretched our experimental design a little further by studying subjects not
only on a sodium restricted diet but also when they were adhering to a high salt
diet. This would allow us to define the role of sodium in the modulation of plasma
and tissue Angll. As expected and often described before, high sodium intake
blunted all effects of enalaprilate, when given alone. Interestingly, though, we
could not find any effect of diet on the alleged tissue Angll. Notably, renal
responses were similar on both diets. Since a high salt diet also depletes the kidney
from renin and angiotensin II, it is likely that during ACE-inhibition the kidney
was equally 'hungry' for Angll on both diets. This would explain why both the
renovascular and the renin-suppressing action of Angll were similar on both diets
when plasma Angll was held constant.
In conclusion, the results of our experiments lend support for the theory that
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tissues can both convert circulating AngI into AngIT and extract AnglT from the
circulation. A special situation seems to exist in the kidney where Angll may exert
a prolonged action. The uptake of Angll in renal tissue is probably enhanced under
conditions of intrarenal Angll depletion. The latter occurs during ACE-inhibition or
during high salt intake. Both conditioas render the kidney hungry for Angll.
• • • • • • • *
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Summary and
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Summary and concluding remarks
This thesis deals with two important aspects of blood pressure control: body
sodium and the renin-angiotensin system. Over the past century both factors have
received ample attention in the literature. Still, their respective roles in the
pathogcnesis and maintenance of hyperteasion are only poorly understood.
Normally, an increase in sodium intake with a concurrent rise in body sodium
will suppress renin, angiotensin and aldosterone. With a reduction in sodium intake
the opposite occurs. The renin-angiotensin-aldosterone system is primarily a system
involved in the homeostasis of body sodium but it has also clear blood pressure
raising effects. A disturbed balance between body fluid volumes and the activity of
the renin-angiotcnsin system may, therefore, have pathophysiological significance,
not only in hypertension but also in, for instance, congestive heart failure.
The aim of the present thesis was to explore in more detail some fundamental
aspects of sodium handling by the kidney and the role of the renin-angiotensin
system as a function of sodium balance. . r i. 5 .-.'
In chapter 1 a brief introduction is given about hypertension, some
pathophysiological mechanisms in this disorder and the general aims of the studies.
In chapter 2 the response of the kidney to a sudden reduction in sodium intake
is explored. As it is generally assumed that urinary sodium output falls according
to an exponential function, the rate constant of the decay function must vary
considerably between individuals if one is to explain large variations in cumulative
sodium loss between individuals. To examine differences in sodium output
following sudden sodium restriction, ninety untreated essential hypertensives were
admitted to a metabolic ward for seven days and put on a sodium restricted diet of
55 mmol/day. In these patients changes in urinary sodium excretion were rather
variable and could be described by at least four different patterns. One group
gradually reached sodium balance according to an exponential function, whereas
another group showed an abrupt fall in sodium excretion on the third day of
sodium restriction and an extremely fluctuating sodium excretion thereafter. A third
group reached sodium balance on day four, but displayed a rise in sodium
excretion during the following days and a fourth group attained sodium balance
only very slowly or not at all. Compared to the others, the latter group lost more
sodium and at the same time displayed a greater fall in blood pressure.
On the basis of these data we concluded that there are multiple patterns by which
sodium balance can be reached following a reduction in sodium intake.
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In chapter 3 we investigated whether a certain degree of sodium sensitivity of
blood pressure in essential hypertensives during sodium restriction is related to
cumulative sodium loss. To this end one hundred and seventeen untreated essential
hypertensives were admitted to a metabolic ward for seven days and put on a
sodium restricted diet of 55 mmol/day. During these seven days urinary excretion
of sodium was determined daily and so was blood pressure. Active plasma renin
concentration and some other variables were assessed after seven days under steady
state condition.
Based on the final changes in blood pressure the population was divided into
tertiles with fertile 1 displaying the greatest fall in blood pressure from day 1 to
day 7 and tertile 3 showing almost no change in blood pressure. The data from this
study show that cumulative sodium losses were similar between the tertiles and that
changes in blood pressure are not correlated to the amount of sodium lost by the
body. However, levels of renin appeared to be significantly higher in tortile 3 as
compared to tertile 1 which was the most sodium sensitive one. Therefore, the data
suggest that sodium sensitivity of blood pressure in essential hypertensive subjects
is not determined by sodium status, but rather by renin. In addition, the results
indicate that sodium sensitivity is a gradual phenomenon and that one should not
dichotomize patients into a sodium sensitive and a sodium resistant group simply on
the basis of an arbitrary cut-off point.
In chapter 4 these observations were stretched a little further. The purpose of
the study presented in that chapter was to explore whether the degree of sodium
sensitivity of blood pressure depends upon renin activation during steady state or
upon initial renin activation during the first days of sodium restriction. This study
was carried out in sixty-seven untreated essential hypertensive patients along the
same lines as the study presented in chapter 3. Besides measurements in steady
state condition (after seven days) active plasma renin concentration and aldosterone
were also assessed during the first three days of sodium restriction. The results of
this study show that both baseline sodium excretion and the activation of renin
during the first three days predict total sodium loss after seven days. Changes in
blood pressure were not related to changes in sodium balance, but they were to
baseline blood pressure and renin activation during the early phase of sodium
restriction. In addition, blood pressure appeared to fall more when the normal
relationship between sodium loss and early (but not late) activation of renin was
disturbed. It was concluded that sodium sensitivity of blood pressure during sodium
restriction is linked to a relative unresponsiveness of the renin system during the
early phase of sodium loss rather than to absolute renin levels during steady state.
125
Because the importance of the renin-angiotensin system had been amply
demonstrated by the foregoing studies, attention was now directed towards the
function of this system in normal men. The second part of this thesis, therefore,
deals specifically with angiotensin I conversion and tissue effects of angiotensin II.
In chapter 5 the systemic and renal effects of equimolar doses of angiotensin I
and angiotensin II were compared in order to determine whether the effects of
angiotensin I can be fully explained by conversion of angiotensin I into angiotensin
II in the plasma compartment. To this end ten healthy volunteers who were in
balance on a sodium-restricted diet were studied on two separate occasions during
which, in random order, infusions of either angiotensin I or angiotensin II were
given in stepwise increasing doses. Mean arterial pressure heart rate, effective
renal plasma flow, glomerular filtration rate, renin, angiotensin I, angiotensin II
and aldosterone were assessed at baseline, after each dose of angiotensin I or II and
thirty minutes and sixty minutes after discontinuation of these infusions.
The results of these experiments indicate that the rise in angiotensin II was
significantly lower during the angiotensin I infusion than during the angiotensin II
infusion (p<0.05). The increments in blood pressure and aldosterone and the
decrease in glomerular filtration rate, however, were comparable during both
infusion regimens. In the kidney, on the other hand, the fall in renin and renal
plasma (low during the angiotensin II infusion exceeded those during infusion of
angiotensin I (p<0.05). After cessation of either infusion, angiotensin II
concentrations returned to baseline as did blood pressure, renal plasma flow and
aldosterone. Only renin remained significantly inhibited (p<0.05). These data
strongly suggest that the effects of angiotensin I on blood pressure and aldosterone
release may be brought about by angiotensin II, formed, at least partly, from
angiotensin I at tissue sites. However, due to a low capacity of the kidney to
convert angiotensin I, the renal effects of angiotensin I are less prominent than
those of angiotensin II. The longer-lasting inhibition of renin after cessation of the
angiotensin infusion points towards accumulation of angiotensin II in the kidney.
In chapter 6 it is examined whether it is possible to discriminate between the
effects of tissue and plasma angiotensin II in man. To this end the ACE-inhibitor
enalaprilate was either infused alone or together with an infusion of angiotensin II.
With the latter manoeuvre plasma angiotensin II levels were maintained at baseline
levels. Comparison of both infusion regimens allowed to discriminate between
effects that are entirely dependent upon plasma angiotensin II versus those that are
related to tissue angiotensin II. This study shows that maintenance of plasma
angiotensin II during ACE-inhibition elicits renal vasoconstriction and incompletely
suppresses renin. while leaving blood pressure and aldosterone levels unchanged.
After cessation of the angiotensin II infusion, renal vasoconstriction persists and the
more so when higher doses of angiotensin II had been used. These effects could be
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related to renal uptake of angiotensin IT from the circulation.
To explore whether the tissue effects of angiotensin II are modified by alterations
in sodium intake, the same study was undertaken in volunteers during both a low
and a high sodium diet. Data from this study, described in chapter 7 clearly
demonstrate that most effects of ACE-inhibition are sodium-dependent when plasma
angiotensin II is allowed to fall. When plasma angiotensin II is maintained,
however, the observed effects are similar on both diets. The most likely
explanation for these observations is that the infusion of angiotensin II had loaded
the tissues (in particular the kidney) with this peptide which was subsequently
protected from degradation for some time.
When all the data from this study are taken together, it can be concluded that the
renin-angiotensin system plays a key role in determining the degree of sodium
sensitivity. Whereas it is still unknown why activation of renin fails in some
people, it seems that an unresponsive renin system carries the risk of too great a
volume loss during sodium restriction. One can now entertain the hypothesis that
under such conditions blood pressure has to fall in order to limit further sodium
losses. This hypothesis needs to be tested in future experiments.
The renin-angiotensin system exerts its effects both through circulating
angiotensin II and through angiotensin II that is present in tissues, notably the
kidney. The data in this thesis lend support to the hypothesis that tissue depletion
of angiotensin II may make tissue 'hungry' for this peptide. Specifically, this seems
to be true in the kidney. It is worthwhile, therefore, to test this hypothesis in more
detail and to assess whether ACE-inhibitors with different lipophilicity have
different effects on tissue levels of angiotensins.
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Chapter 10
Samenvatting
Samenvatting
Dit proefschrift belicht twee belangrijke aspecten van de bloeddrukregulatie: de
zouthuishouding van het lichaam en het renine-angiotensine systeem. Gedurende de
laatste eeuw zijn beide aspecten ruimschoots in de literatuur aan bod geweest.
Dcsalnicticmm is hun beider rol in het ontstaan en het onderbouden van hypertensie
nog steeds onvoldocnde bekend. •  * * ;' :
Onder normale omstandigheden leidt een toename van zoutconsumptie met een
gelijklijdigc stijging van het lichaams nairiurrH = /out) tot onderdrukking van het
renine-angiotensine-aldosteron systeem. Het tegenovergestelde gebeurt wanneer het
zoutgebruik wordt gereducecrd. Het renine-angiotensine-aldosteron systeem is
echler niet allcen betrokken bij de homeostase van het lichaamsnatrium en
(indirect) het circulcrend volume, maar ook beinvloedt dit systeem de bloeddruk.
Een verst(H>rde halans tussen het circulerend volume en de activiteit van het renine-
angiotensine systeem kan daarom pathofysiologisch van betekenis zijn, niet alleen
in het geval van hypertensie, maar ook bijvoorbeeld bij hartfalen.
Dit proefschrift beoogt enkele fundamentelc aspecten van het renine-angiotensine
systeem in het kader van de re^ulalie van /outbalans en hloeddnik te besmderen
In hooldstuk 1 wordt een korte inleiding gegeven over hypertensie, enkele
pathofysiologische mechanismen van deze aandoening en de algemene vraag-
stellingcn die leidden tot de in dit proefschrift beschreven studies.
In hoofdstuk 2 wordt de reactie van de nier op een acute vermindering van de
zoutconsumptie bestudeerd. Indien, zoals tot nu toe werd verondersteld, de
zoutexcretie door de nier afneemt volgens een exponentiele functie, dan zal de snel-
hcidsconstante van deze funclie aanzienlijk moeten verschillen tussen individuen,
als men tenminste de grole verschillen in het cumulatieve zoutverlies tussen ver-
schillende patienten wil verklaren. Om mogelijke inter-individuele verschillen in
zoutuitscheiding na een acute reductie in het zoutgebruik te onderzoeken, werden
negentig patienten met essentiele hypertensie gedurende zeven dagen opgenomen.
Gedurende deze opname nuttigden zij een zoutbeperkt dieet van 55 mmol natrium
( = 3 gram zout) per dag. In deze patienten waren de veranderingen in de
zoutexcretie zeer variabel en kon het beloop van de 24 uurs natriumexcretie worden
beschreven aan de hand van tenminste vier verschillende patronen. Een groep
kwutn geleidelijk in /outbalans. volgens een exponentiele functie. terwijl een
andere groep initieel een abrupte daling van de zoutexcretie liet zien gevolgd door
een zeer fluctuerende excretie. De derde groep kwam in zout balans op de vierde
dag. maar liet een duidelijke stijging zien in natriumexcretie gedurende de
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daaropvolgende dagen, terwijl de vierde groep slechts zeer langzaam of geheel niet
in balans kwam. Vergeleken met de andere groepen. verloor deze laatste groep dan
ook het meeste zout en vertoonde daarbij ook een sterkere daling in de bloeddruk.
Aan de hand van deze gegevens werd geconcludeerd dat er verschillcndc patroncn
zijn waarmee individuen na een plotse vermindering van het zoutgebruik in halans
geraken. • : •: s ,• • -. . ' : •.,
In hoofdstuk 3 werd vervolgens onderzocht of een zekere mate van zoutge-
voeligheid van de bloeddruk in patienten met essentiele hypertensie gedurende
zoutrestrictie gerelateerd is aan het cumulatieve zoutverlies. Om dit na te gaan
kregen honderdenzeventien onbehandelde hypertensieve patienten gedurende zeven
dagen een zoutbeperkt dieet van 55 mmol natrium ( = 3 gram /.out) per dag.
Gedurende deze zeven dagen werden zowel de natriumexcretie in de 24 uurs urine
als de bloeddrukveranderingen vastgelegd. De actieve plasma renine concent ratio en
enkele andere variabelen werden gemeten na zeven dagen in de 'steady state'
situatie.
Aan de hand van de uiteindelijke veranderingen in bloeddruk werd de onderzochte
populatie in tertielen verdeeld, waarbij tertiel 1 de grootste bloeddrukdaling ten
toon spreidde van dag een tot dag zeven, terwijl in tertiel 3 vrijwel geen hloecklruk-
verandering optrad. De resultaten van deze studie lieten zien dat hot cumulatieve
zoutverlies in de drie tertielen gelijk was en dat de veranderingen in bloeddruk niet
gecorreleerd zijn aan het totale zoutverlies van het lichaam. De steady state renine
concentraties, bleken echter in tertiel 3 hoger te zijn dan in tertiel 1 (het meest
zoutgevoelige tertiel). Deze uitkomsten pleiten voor de hypothesc dat de zoulgcvoe-
ligheid van de bloeddruk in essentieel hypertensieve patienten niet word bepaald
door de zoutbalans, maar eerder door het renine. Bovendien tonen deze resultaten
nog eens dat zoutgevoeligheid van de bloeddruk een gradueel fenomeen is en dat
patienten niet geclassificeerd kunnen worden als zoutgevoelig of zoulongevoelig op
grond van een arbitrair afkappunt.
In hoofdstuk 4 werden deze waarnemingen nog wat verder uitgediept. Het doel
van de in dit hoofdstuk beschreven studie was om te ontdekken of de mate van
zoutgevoeligheid van de bloeddruk afhankelijk is van de mate van renine-activatie
tijdens steady state of van de renine activatie gedurende de eerste paar dagcn van
de zoutbeperking. Deze studie werd uitgevoerd in zevenenzestig onbehandelde
hypertensiepatienten, grotendeels volgens hetzelfde protocol als dat van de studie in
hoofdstuk 3. Naast bepalingen in steady state (na zeven dagen) werden het renine
en het aldosteron ook bepaald gedurende de eerste drie dagen van de zout-
beperking. De resultaten van deze studie laten zien dat zowel de initiele
zoutexcretie als de activatie van het renine gedurende de eerste drie dagcn ccn
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voorspellende waarde hebben voor hei uiteindelijke zoutverlies na zeven dagen. De
veranderingen in bloeddruk waren ook nu niet gerelateerd aan veranderingen in de
zoutbalans, maar wel aan de initiele bloeddruk en de mate van renine activatie
gedurende de vroege fase van de zoutrestrictie. Bovendien leek de bloeddruk meer
le dalcn wanneer de normale relatie tussen zoutverlies en de vroege activatie van
renine verstoord was. Hieruit werd geconcludeerd dat de zoutgevoeligheid van de
bloeddruk tijdens zouthcperking eerder gekoppeld lijkt aan een relatieve ongevoe-
ligheid van hct renine systeem gedurende de vroege fase van het zoutverlies dan
aan de absolute renine concentraties gedurende steady state.
Aange/.ien de bctrokkenhcid en relevantie van het renine-angiotensine systeem
duidclijk was aangctoond in de voorgaandc studies, werd de aandacht vervolgens
gcricht op de functie van dit systeem in de gezonde meas.
Het twcede gedeelte van dil proefschrift gaat dan ook over de conversie van
angiotensinc I en dc weefselcffecten van angiotensine II.
In hoofristtik 5 wcrden de systemische en renale effecten van equimolaire
hocvcclhcdcn van angiotensinc I en angiotensine II vergeleken om te kunnen
hepalen of de effecten van circulerend angiotensinc I geheel kunnen worden
verklaard door om/ctting van angiotensine I in angiotensine II in het plasma
compartiment. Hiervoor werden tien gezonde vrijwilligers, in zoutbalans op een
zoutheperkt dieet, op twee verschillende dagen onderzocht. Gedurende deze
experimenten werd in willekeurige volgorde, ofwel angiotensine I ofwel
angiotensine II in oplopcnde doseringen toegediend. De gemiddelde bloeddruk, de
effectieve nierd(H)rbloeding en glomerulaire filtratiesnelheid, alsmede het renine,
het angiotensine I en II en het aldosteron werden bepaald bij de start, na iedere
dosis angiotensine I of II en respectievelijk dertig en zestig minuten na het stoppen
van de infusies.
De resultaten van deze experimenten geven aan dat de stijging van het plasma
angiotensine II na angiotensine I infusie significant kleiner was dan na angiotensine
II infusie. De stijging in bloeddruk en aldosteron concentratie aan de ene kant en
de daling in glomerulaire filtratiesnelheid aan de andere kant waren niet
verschillend gedurende beidc infusies. Dit in tegenstelling tot de daling van het
renine en de nierdoorbloeding welke gedurende de angiotensine II infusie duidelijk
sterker was dan gedurende de angiotenine I infusie. Na het stoppen van beide
infusies daalden de angiotensine II concentraties naar het uitgangs niveau. evenals
de bloeddruk. de nierdoorbloeding en het aldosteron. Alleen het renine bleef
significant onderdrukt. Deze uitkomsten suggereren dat de effecten van
angiotensine I op de bloeddruk en de aldosteron afgifte kunnen worden verklaard
door omzetting van angioiensine I in angiotensine II. waarbij conversie
waarschijnlijk ten dele op weefselniveau plaatsvindt. In de nier echter zijn de
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effecten van angiotensine I minder uitgesproken dan die van angiotensine II. Dit
hangt mogelijk samen met een lage angiotensine-omzetiingscapaciieit in de nier. De
nog voortdurende renine-inhibuie na het stoppen van de angiotensine inlusies wijst
mogelijk op accumulatie van angiotensine in de nier.
In hoofdstuk 6 wordt vervolgens onderzocht of het mogelijk is onderscheid te
maken tussen de effecten van weefsel en plasma angiotensine II in do mens.
Daartoe werd de ACE-remmer enalaprilaat of wel alleen of wel in combinatie met
angiotensine II geinfundeerd. Met deze angiotensine II infusie werd beoogd de
plasma concentrates van angiotensine II op uitgangsniveau (e houden. Het vergelijk
tussen de twee infusieschema's (enalaprilaat alleen versus de gecombineerdc infusie
met angiotensine II) maakte het mogelijk om onderscheid te maken tussen effecten
welke volledig afhankelijk zijn van het plasma angiotensine II en de effeclen
gerelateerd aan een extraplasmatisch mechanisme, waarschijnlijk het weefsel
angiotensine II. Deze studie laat zien dat het handhaven van plasma angiotensine II
spiegels tijdens ACE-inhibitie gepaard gaat met vasoconstrictie in de nier en een
onvolledige suppressie van het renine, terwijl bloeddruk en de aldosteron spiegels
onveranderd blijven. Na het beeindigen van de angiotensine infusie blijft de rciule
vasoconstrictie voortduren. Deze vasoconstrictie is zelfs sterker naarmate
voorafgaand een hogere dosis angiotensine II is geinfundeerd. Dergelijke effecten
zouden verklaard kunnen worden doordat de nier angiotensine II vanuit de
circulatie opneemt en opslaat.
Om te kunnen bepalen of de weefseleffecten van angiotensine II worden beinvloed
door zout, werd dezelfde studie uitgevoerd bij vrijwilligers tijdens zowel een
zoutbeperkt als een zoutverrijkt dieet. De uitkomsten van deze studie, beschreven
in hoofdstuk 7 geven duidelijk aan dat de meeste effecten van ACE-inhibitie
zoutafhankelijk zijn, als het plasma angiotensine II daalt. Wanneer echter het
plasma angiotensine II gelijk wordt gehouden, zijn de effecten van ACE-inhibitie
op beide dieten gelijk. De meest aannemelijke verklaring voor deze waarnemingen
is dat de angiotensine II infusie de verschillende weefsels (met name de nier) heeft
opgeladen met dit peptide dat vervolgens in deze weefsels gedurende enige tijd
wordt beschermd tegen afbraak.
Wanneer alle uitkomsten van het in dit proefschrift beschreven onderzoek in
ogenschouw worden genomen, kan worden geconcludeerd dat het renine-
angiotensine systeem een sleutelrol speelt bij het bepalen van de mate van
zoutgevoeligheid. Hoewel het nog steeds onbekend is, waarom in sommige mensen
het renine niet adequaat reageert, lijkt het erop dat een niet reagerend renine een
groter volumeverlies tijdens de fase van zoutbeperking tot gevolg heeft. Men zou
zelfs kunnen beredeneren dat onder zulke omstandigheden de bloeddruk wel moct
dalen om het zoutverlies zoveel mogelijk te beperken. Deze hypothese moet in
133
toekomstige experimenten getest worden.
Het renine-angioteasine systeem oefent zijn effect uit via enerzijds het circulerende
angiotensine II en anderzijds het angiotensine II dat aanwezig is in de weefsels, met
name in de nier. De resultaten van de in dit proefschrift beschreven studies
ondcrbouwen de hypothese dat depletie van angiotensine II in de weefsels deze
weefsels "hongerig" maakt voor dit peptide. Dit lijkt met name het geval te zijn in
de nier. Het is daarom de moeite waard om deze hypothese verder te toetsen en te
bezien of bijvoorbeeld ACE-remmers met verschillende lipofiliciteit ook
verschillcnde effecten veroorzaken met betrekking tot de weefsel concentraties van
angiolcnsines.
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Dankwoord
Aan het begin van mijn AlO-schap leefde ik nog in de veronderstelling dat een
promotieonderzoek toch wel in twee jaar kon worden afgerond. Dit idee
veranderde echter al heel snel. Vlak na het vertrek van mijn toenmalige co-promo-
tor werd alle hoop op een voorspoedig einde de bodem ingeslagen en meende ik
dat ik de voorgeschreven termijn van vier jaar zou gaan overschrijden. Dal het
uiteindelijk drie jaar geworden is, zegt niet zoveel over mijn inzet en werklust, als
wel over die van een aantal belangrijke sleutelfiguren rondom mij. Zonder hen was
het nooit gelukt!!!
Allereerst mijn promotor Prof, dr P.W. de Leeuw, met wie dit dankwoord
begint, maar ook zal eindigen. Beste Peter, de afgelopcn tweeenhalf jaar ben je niet
alleen mijn promotor geweest, maar tevens ook een onnavolgbare co-promotor.
Daar waar andere promotoren zich alleen bezig houden met de zgn. finishing
touch, ben jij bij ieder onderdeel van dit promotie-onderzoek onmisbaar gebleken.
Zonder jouw heldere kijk op mijn wetenschappelijke zaak had dit boekje zcker
langer op zich laten wachten. Vooral wat betreft de analyse van de onder/.oeksre-
sultaten waren jouw invallen (met name die na een uur 's nachts) keer op keer van
onschatbare waarde. Ik heb veel van je geleerd en het feit dat het proefschrift nu
klaar is, betekent gelukkig niet dat onze samenwerking ten einde is.
Verder wil ik mijn andere promotor Prof, dr H.F.P Hillen bedanken voor zijn
bijdrage aan de 'eindspurt'. Beste Harry, zonder jouw aansporing en bovendien
jouw vertrouwen dat het me zou lukken was dit boekje niet in 1996 verschenen.
Zonder de steun van de mensen van het hypertensie-lab was het onderzoek niet
alleen een onmogelijke maar ook een saaie taak geweest. E6n van de juwelen van
het hypertensie-lab is ongetwijfeld Monique Fuss. Beste Monique, geruisloos en
schijnbaar moeiteloos heb je bergen werk verzet in het kader van mijn promotie-
onderzoek. Ondanks de smakeloze dieten deden, mede door jouw opgewektheid,
veel patienten en proefpersonen maar wat graag mee aan een angiotensine "experi-
mentje' op lab 1. Ook nu weer in de hoedanigheid van paranimf kan ik op je
rekenen.
Boy Houben, Paul van Es, Claudia de Haan en Arie Lavrijssen hebben mij weg-
wijs gemaakt wat betreft de bediening van alle apparatuur. Boy, jij hebt mij de
kunst van de conjunctiva metingen bijgebracht. Alhoewel de resultaten niet in dit
proefschrift zijn beschreven gaan we dat zeker nog een keer doen in de vorm van
artikelen. Gusta Frijns en Paul van Es wil ik beide bedanken voor de gezellige
samenwerking in het kader van alle klinische trials, die naast het promotie-
onderzoek ook gewoon doorgingen.
Wie nu denkt dat er alleen gewerkt werd, heeft het mis. Het hypertensie-lab of
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een gedeelte ervan was regelmatig te vinden bij 'Da Roberto' of bij de Griek.
De afgelopen jaren hebben een aantal studenten zich belangeloos ingezet voor
mijn onderzoek. Sergio Rodriguez, Astrid Otten, Wilco Spiering en Jeroen
Renzcma hebben de werklast aanzienlijk verlicht. Met name Sergio is
onlosmakelijk verbonden met hct onderzoek. Deze 'regelneef (en dat is eerbiedig
bcdocld) weel allcs en iedereen in le zetten voor het goede wetenschappelijke doel.
Dank aan Nicolaas Schaper, Frank Huvers, Bram Kroon, Erik van Beek en Louis
Peelers, die naasl de vaste hypertensie kern iedere donderdagavond deel uitmaakten
van het wetcaschappelijke brainstorm groepje en op deze manier bijdroegen aan het
bijsturen van mijn onderzoek.
De afdeling dictetick en in het bijzonder Lianne Schoorlemmer ben ik erkentelijk
v(M>r het verzorgen van dc dieten van al die patienten en proefpersonen die aan het
onderzoek mcededen.
Verder ben ik het neurohumorale lab dank verschuldigd. Jet Bost, Geertje
Swcnnen en Paul Schiffers hebben de afgelopen jaren niet zelden onder grote
werkdruk de ontelbare neurohumorale monsters bepaald.
Tocn ik al begonnen was in het Maaslandziekenhuis heeft Tiny Wouters de lay-
out van dit proelschrilt geheel op haar schouders genomen, zodat haar wat dit
bctreft alle ccr toekoml.
De leden van de beoordelingscommissie. Prof, dr H.A.J. Struyker Boudier,
Prof, dr M.P. van Dieijen-Visser en Prof, dr H.J.J. Wellens wil ik danken voor
het krilisch beoordelen van mijn manuscript. I also would like to thank Prof, dr
N.K. Hollenberg and Prof, dr H.R. Brunner for their willingness to review my
manuscript and to be present at my thesis defense.
Mijn beide ouders wil ik bedanken voor hun nimmer aflatende vertrouwen in
my. Lieve Mam en Pap, zonder jullie steun en liefde was het allemaal niet
mogclijk geweest. Ook in deze fase van mijn leven is jullie hulp van vitaal belang
gebleken, want in de/.e laatste maanden hebben jullie heel wat uurtjes op Diederick
gelet, zodat ik mij met een gerust hart kon wijden aan het schrijven van dit boekje.
Mijn zus Anne Marie ben ik dankbaar voor het feit dat ze ondanks haar eigen
drukke werkzaamheden mijn paranimf wou zijn.
Diederick, lief kereltje, dank je voor de uurtjes die we met z'n drieen hebben
doorgebrachl, pappa en ik achter de computer en jij in de Maxi Cosi op de grond.
Nu het boekje klaar is gaan we ook eens wat leukere dingen doen.
Lieve Peter, zoals bcloofd aan het begin van dit dankwoord ben jij ook degene
met wie ik eindig. Zo is de cirkel rond. Niet minder beiangrijk dan de rol van
promotor was je rol als mijn partner. Afgezien van jouw wetenschappelijke steun
had ik jouw emotionele steun niet kunnen ontberen.
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Marielle Krckels werd geboren op 20 december 1967 te 's-Gravenhage. In 1986 bchaalde
zij het gymnasium-R diploma aan het Gymnasium Sorghvliet te 's-Gravenhage Omdat /.ij
werd uitgeloot voor de studie Geneeskunde. startle zij dat jaar met de studic Biologic aan
de Rijksuniversiteit Leiden. Het jaar daarop. in 1987. begon zij met de studie
Geneeskunde aan de Erasmus Universiteit in Rotterdam. Als .V en 4'-jaars studentc was
zij werkzaam als student-assistent op het Endocrinologic laboratorium (Hoofd: Prof, dr
J.C. Birkenhager en Prof, dr G. Hennemann) Gedurende haar doctoraal perkxle liep zij
een stage Interne Geneeskunde in Engeland (Queen Elisabeth Hospital. Birmingham,
hoofd: Prof, dr M. Shepard) en een suge Gynaecologie in Italie (Ospedale Univcrsita di
Bari, Ban. hoofd: Prof, dr L. Selvaggi). In 1993 behaalde zij cum laude net artscxamen
waarna zij in datzelfde jaar begon als assistent in opieiding (AIO) bij dc wcrkgrocp
Nefrologie/Hypertensie/Transplantatie (Hoofd: Prof, dr P.W. de Ixreuw), Vakgrocp
Interne Geneeskunde, AZM/RL en Cardiovascular Research Institute Maastricht
(CARIM). Van november 1993 tot en met juni 1996 werkte de auteur aan de in dit
proefschrift beschreven experimenten. In april 1996 ontving zij daarvoor dc ecrstc prijs in
het kader van de promovendi-competitie ter gelegenhcid van tien jaar academiscring van
het AZM. Vanaf oktober 19% is zij aangesteld als assistent geneeskundige nict in
opieiding op de afdeling Interne Geneeskunde van het Maaslandziekenhuis alwaar zij per
1 april 1997 zal beginnen met de opieiding tot internist (opleider: Dr. B.J Looij).
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